Therapeutic,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Jan '20),Est. Status,Heavy Sequence,Light Sequence,Heavy Sequence (if bispec),Light Sequence (if bispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes
Abagovomab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS,DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK,na,na,None,None,None,2006,2007,CA125,Menarini,na,na,Ovarian cancer;Pancreatic cancer ,na,
Abelacimab,Whole mAb,G1,Lambda,Unknown,Unknown,QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRATAVYYCARELSYLYSGYYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYAWDQRQFDVVFGGGTKLTVL,na,na,None,None,6r8x:CB,2018,2019,F11,Novartis,na,Thromboembolism,na,na,
Abituzumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,na,na,None,None,None,2013,2014,ITGAV,Merck,na,Systemic scleroderma ,Colorectal cancer;Ovarian cancer;Prostate cancer;Solid tumours ,na,"4o02 claims to be abituzumab (17E6), but is not"
Abrezekimab,Fab,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVATYYCARDGTIAAMDYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGYRFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL13,UCB,na,na,Asthma,na,
Abrilumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2014,2015,α4β7,Amgen;AstraZeneca,na,na,Crohn's disease;Ulcerative colitis ,na,
Acapatamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,FOLH1;CD3E,TBC,TBC,TBC,TBC,na,
Actoxumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,Toxin A,Bristol-Myers Squibb;Merck;University of Massachussets Medical School,na,na,Clostridium difficile,Medarex HuMAb Mouse,
Adalimumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,na,na,6cr1:HL/4nyl:AB:CD:EF:HL,3wd5:HL,None,1999,2000,TNFA,Abbvie;MedImmune,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis ,Pyoderma ,Interstitial cystitis ,CAT Phage Display,
Adebrelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2019,na,PDL1,Jiangsu Hengrui Medicine,na,Solid tumours;Carcinoma,na,na,
Aducanumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,6cnr:HL/6co3:HL,None,None,2013,2014,APP,Biogen;Neurimmune,na,na,Alzheimer's disease ,na,
Afasevikumab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,na,na,6ppg:HL:AB,None,None,2015,2016,IL17A,NovImmune;Genentech,na,Inflammation,Autoimmune disorders,na,
Afutuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,na,na,3pp3:HL:IK/3pp4:HL,None,None,2008,2011,MS4A1,GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds,Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia,Primary biliary cirrhosis,GlycoMAb Technology,Obinutuzumab and Afutuzumab are the same mAb
Alacizumab,di-Fab,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK,na,na,None,None,None,2007,2008,KDR,UCB,na,na,Non-small cell lung cancer ,na,
Alemtuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,na,na,1bey:HL/1ce1:HL,None,None,2000,2001,CD52,Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge,Chronic lymphocytic leukaemia;Multiple sclerosis ,Lymphoma;T-cell prolymphocytic leukaemia ,Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma ,na,
Alirocumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital,Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis,Coronary artery disease,na,VelocImmune Mouse,
Alnuctamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,TNFRSF17;CD3E,TBC,TBC,TBC,TBC,na,
Alsevalimab,Whole mAb,G1,Kappa,Phase-I,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK,na,na,None,None,None,2019,na,VTCN1,Five Prime Therapeutics,na,Solid tumours,na,na,
Amatuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK,na,na,None,4f33:BA:DC:FE:HG/4f3f:BA,None,2010,2011,MSLN,Eisai Co Ltd;Morphotek;National Cancer Institute (USA),na,Mesothelioma,Pancreatic cancer;Solid tumours ,na,
Amivantamab,Bispecific mAb,G1,Kappa;Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,None;None,None;None,None;None,2019,2020,EGFR;MET,Genmab;Janssen Research & Development,na,Non-small cell lung cancer,na,na,
Andecaliximab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK,na,na,5th9:HL:IM:JN,None,None,2016,2017,MMP9,Gilead Sciences,na,Gastric cancer;Solid tumours;Glioblastoma,Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis,na,
Anetumab,Whole mAb ADC,G1,Lambda,Phase-II,Active,QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL,na,na,None,None,None,2013,2014,MSLN,Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) ,na,Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer,Non-small cell lung cancer ,MorphoSys HuCAL Phage Display,
Anifrolumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,na,na,4qxg:HL,None,None,2013,2014,IFNAR1,Medarex;Medical University of Vienna;MedImmune,na,Systemic lupus erythematosus;Lupus nephritis;Rheumatoid arthritis,Scleroderma,Medarex UltiMAb Mouse,
Anrukinzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2007,2008,IL13,Pfizer;Wyeth,na,na,Asthma;Ulcerative colitis,na,
Apamistamab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Active,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS,DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,PTPRC,Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Hodgkin's disease;Non-Hodgkin's lymphoma,na,
Apitegromab,Whole mAb,G4,Lambda,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL,na,na,None,None,6umx:hl,2020,na,pro-GDF-8,TBC,TBC,TBC,TBC,na,
Aprutumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL,na,na,None,None,None,2016,2017,FGFR2,Bayer,na,na,Solid tumours,na,
Ascrinvacumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,na,na,None,None,None,2015,2016,ACVRL1,Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals,na,Age-related macular degeneration;Cancer;Liver Cancer,Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer,na,
Astegolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL1RL1,Amgen;Genentech;University of Leicester,na,Allergic asthma;Asthma;Atopic dermatitis;Chronic obstructive pulmonary disease,na,na,
Atezolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,na,na,5x8l:FK:HM:GL:JO:SN,5xxy:HL,None,2014,2015,CD274,Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University,Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer,Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma,Hodgkin's disease;Myelodysplastic syndromes,Human Phage Display,
Atidortoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,na,
Atinumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK,na,na,None,None,None,2010,2011,RTN4,Novartis,na,na,Spinal cord injuries,na,
Atoltivimab,Whole mAb,G1,Kappa,Preregistration,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK,na,na,None,None,None,2018,na,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,na,na,Ebola virus infections,na,
Avdoralimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,C5AR1,Novo Nordisk;Innate Pharma,na,Solid tumours,Rheumatoid arthritis,na,
Avelumab,Whole mAb,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma,Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains
Avizakimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL21,MedImmune;Boston Pharmaceuticals,na,Systemic lupus erythematosus;Autoimmune disorders,na,na,
Axatalimab,Whole mAb,G4,Kappa,Unknown,Active,EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK,na,na,None,None,None,2019,2020,CSF1R,na,na,na,na,na,
Azintuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS,DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK,na,na,None,None,None,2016,2017,SLAMF7,AbbVie,na,na,Multiple myeloma,na,
Balstilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK,na,na,None,None,None,2018,2019,PDCD1,Agenus;Ludwig Institute for Cancer Research,na,Cervial cancer;Solid tumours,na,na,
Bapineuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,na,na,None,None,4ojf:HL/4hix:HL,2005,2006,APP,JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation,na,na,Alzheimer's disease,na,"Jain paper: ""Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL"""
Bapotulimab,Whole mAb,G2,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR,na,na,None,None,None,2020,na,ILDR2,TBC,TBC,TBC,TBC,na,
Barecetamab,Whole mAb,G1,Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL,na,na,None,None,None,2020,na,ERBB3,TBC,TBC,TBC,TBC,na,
Basiliximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,na,na,1mim:HL/3iu3:AB:CD:HL,None,None,1996,1997,IL2RA,Cerimon Pharmaceuticals;Novartis,Renal transplant rejection;Transplant rejection,na,Ulcerative colitis;Uveitis,na,
Batoclimab,Whole mAb,G1,Lambda,Phase-II,Active,QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS,SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,FCGRT,Immunovant Sciences,na,Graves’ Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura,na,na,
Bavituximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,na,na,None,None,None,2006,2007,Phosphatidylserine,Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center,na,Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours,Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer,na,
Bedinvetmab,Canine Whole mAb,G2,Lambda,Unknown,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS,QSVLTQPTSVSGSLGWRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL,na,na,None,None,None,2018,2019,Canine NGFB,na,na,Canine lupus familiaris,na,na,
Befovacimab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL,na,na,None,None,None,2019,2020,TFPI,na,na,Haemophilia,na,na,
Begelomab,Whole mAb,G2b,Kappa,Phase-II/III,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK,na,na,None,None,None,2014,2015,DPP4,ADIENNE,na,Graft-versus-host disease,na,na,
Belantamab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK,na,na,None,None,None,2017,2018,TNFRSF17,GlaxoSmithKline,na,Multiple myeloma,na,na,
Belimumab,Whole mAb,G1,Lambda,Approved,Active,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,na,na,5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE,None,6erx:HI:DE:QR:MN:FG:OP,2003,2004,TNFSF13B,Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology,Systemic lupus erythematosus,Anti-neutrophil cytoplasmic antibody-associated vasculitis;Lupus nephritis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic scleroderma;Graft-versus-host disease,Waldenstrom's macroglobulinaemia;Rheumatoid arthritis,CAT Phage Display,
Bemarituzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,FGFR2,Five Prime Therapeutics;ZAI Lab,na,Gastric cancer;Oesophageal cancer;Solid tumours,na,POTELLIGENT Technology,
Benralizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,na,na,None,None,None,2009,2010,IL5RA,AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa,Asthma,Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis;Skin disorders,na,POTELLIGENT Technology,
Bentracimab,Whole mAb,G1,Lambda,TBC,Active,QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS,QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL,na,na,5alb:HL,None,5alc:HL,2020,na,AR-C124910XX,TBC,TBC,TBC,TBC,na,
Benufutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF10B,Genmab;VU University Medical Center;iDD Biotech,na,Solid tumours;Multiple myeloma,na,na,
Bepranemab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK,na,na,None,None,None,2019,na,MAPT,UCB BioPharma,na,Progressive supranuclear palsy (PSP),na,na,
Berlimatoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK,na,na,5k59:HL:EF,None,None,2017,2018,Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,na,
Bermekimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,na,na,None,None,None,2018,2019,IL1A,XBiotech Inc.,na,Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis,Haematological malignancies,na,
Bersanlimab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL,na,na,None,None,None,2017,2018,ICAM1,BioInvent International,na,na,Multiple myeloma,n-CoDeR,
Bevacizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ,None,6bft:AB:HL/1cz8:HL:YX,2000,2001,VEGFA,All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital,Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer,Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma,Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer,na,
Bexmarilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK,na,na,None,None,None,2019,na,STAB1,Faron Pharmaceuticals,na,Solid tumours,na,na,
Bezlotoxumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK,na,na,4np4:HL:IM,None,None,2012,2013,Toxin A,Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme,Clostridium difficile,na,na,Medarex HuMAb Mouse,
Bifikafusp,Whole mAb Fusion,E,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,Cancers;Pancreatic cancer;Metastatic melanoma,Brain cancer;Non-small cell lung cancer;Solid tumours,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Bimagrumab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,na,na,5nhr:HL:AB,5nhw:HL/5nh3:HL:IM/5ngv:HL,None,2012,2013,ACVR2B,MorphoSys;Novartis,na,Cachexia;Muscular atrophy;Type 2 diabetes mellitus,Inclusion body myositis,MorphoSys HuCAL Phage Display,
Bimekizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,IL17A,UCB,na,Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Hidradenitis suppurativa;Rheumatoid arthritis;Ulcerative colitis,Psoriasis,na,
Bintrafusp,Whole mAb Fusion,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer,Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains
Birtamimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,SAA1,Neotope Biosciences;Onclave Therapeutics;Prothena,na,na,Amyloid light-chain amyloidosis,na,
Bleselumab,Whole mAb,G4,Kappa,Phase-II,Active,QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK,na,na,None,None,None,2015,2016,CD40,Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin,na,Focal segmental glomerulosclerosis;Renal transplant rejection,Transplant rejection;Plaque psoriasis,na,
Blinatumomab,Bispecific T-Cell Engager,na,Kappa;Kappa,Approved,Active,QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS,DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK,DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,None;None,None;None,None;None,2008,2009,CD19;CD3E,Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis,Precursor B-cell lymphoblastic leukaemia-lymphoma,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,Chronic lymphocytic leukaemia,BiTE Technology,
Blontuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS,DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL,na,na,None,None,None,2015,2016,MS4A1,Aratana Pharmaceuticals,na,Canine B-cell lymphoma,na,na,
Blosozumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,Eli Lilly,na,Postmenopausal osteoporosis,na,na,
Bococizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,3sqo:HL,None,None,2013,2014,PCSK9,Halozyme Therapeutics;Pfizer,na,na,Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia,na,
Brazikumab,Whole mAb,G2,Lambda,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL,na,na,None,None,None,2016,2017,IL23A,Allergan;Amgen;AstraZeneca,na,Crohn's disease;Ulcerative colitis,Psoriasis,na,
Brentuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2010,2011,TNFRSF8,Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine,Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma,Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma,Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus,na,
Briakinumab,Whole mAb,G1,Lambda,Preregistration (w),Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,na,na,5n2k:LK:BA:PO:DC:NM:FE,None,None,2009,2010,IL12B,Cambridge Antibody Technology;Abbott GmbH & Co. KG,na,na,Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis,na,
Brodalumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL17RA,Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis,Spondylarthritis;Systemic scleroderma,Asthma;Crohn's disease;Rheumatoid arthritis,Abgenix XenoMouse,
Brolucizumab,scFv,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS,EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL,na,na,None,None,None,2014,2015,VEGFA,ESBATech;Alcon,Wet age-related macular degeneration,Diabetic macular oedema;Retinal vein occlusion,na,na,
Brontictuzumab,Whole mAb,G2,Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL,na,na,None,None,None,2014,2015,NOTCH1,OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center,na,Colorectal cancer,Adenoid cystic carcinoma;Solid tumours;Haematological malignancies,na,
Budigalimab,Whole mAb,G1,Kappa,Phase-I,Active,EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1,AbbVie,na,Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours ,na,na,
Burosumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK,na,na,None,None,None,2016,2017,FGF23,Kyowa Hakko Kirin;Ultragenyx Pharmaceutical ,X-linked dominant hypophosphataemic rickets,Osteomalacia;Nevus,na,na,
Cabiralizumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK,na,na,None,None,None,2015,2016,CSF1R,Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University,na,Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours ,Rheumatoid arthritis,na,
Camidanlumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL2RA,ADC Therapeutics;Genmab,na,Hodgkin's disease;Non-Hodgkin's lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;Solid tumours,Acute myeloid leukaemia,na,
Camrelizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK,na,na,None,None,None,2016,2017,PDCD1,Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University,Hodgkin's disease,Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma,na,na,
Canakinumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,na,na,None,4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL,None,2007,2008,IL1B,Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich,Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders,Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer,Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Medarex UltiMAb Mouse,
Cantuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS,DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK,na,na,None,None,None,2003,2004,MUC1,ImmunoGen;GlaxoSmithKline,na,na,Gastric cancer;Solid tumours,na,
Caplacizumab,Nanobody,na,na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS,na,na,na,None,None,None,2011,2012,VWF,Ablynx,Thrombotic thrombocytopenic purpura,na,Thrombosis,Nanobody Technology,
Carlumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,na,na,None,4dn3:HL/4dn4:HL,None,2010,2011,CCL2,MorphoSys;Janssen Biotech,na,na,Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours,Human Phage Display,
Carotuximab,Whole mAb,G1,Kappa,Phase-II,Active,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2015,2016,ENG,National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute,na,Wet age-related macular degeneration,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,
Cemiplimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR,na,na,None,None,None,2018,2019,PDCD1,Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center,Squamous cell cancer,Cervical cancer;Non-small cell lung cancer;Basal cell cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;B-cell lymphoma;Cancer;Head and neck cancer;Malignant melanoma;Renal cell carcinoma,na,na,
Cendakimab,Whole mAb,G1,Kappa,Phase-II,Active,EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL13,Abbott Laboratories;AbbVie;Receptos,na,Eosinophilic oesophagitis,Allergic asthma,na,
Cergutuzumab,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,na,na,None,None,None,2015,2016,CEACAM5,Roche,na,na,Solid tumours,na,
Certolizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,na,na,5wuv:HL/5wux:HL:AB:CD,None,None,2004,2004,TNFA,UCB,Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis,Interstitial cystitis;Juvenile rheumatoid arthritis,Cognition disorders,na,
Cetrelimab,Whole mAb,G4,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1,Janssen Research & Development ,na,Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer,na,na,
Cetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC,5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,1999,2000,EGFR,Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center,Colorectal cancer;Head and neck cancer,Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer,Pancreatic cancer;Prostate cancer,na,
Cevostamab,Bispecific mAb,G1,Kappa;Kappa,Phase-I,Active,EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK,None;None,None;None,None;None,2019,na,FCRL5;CD3,Genentech,na,Multiple myeloma,na,na,
Cibisatamab,Bispecific mAb with Domain Crossover,G1,Kappa;Lambda,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,CEACAM5&CD3E;CD3E,Roche,na,Non-small cell lung cancer;Colorectal cancer;Solid tumours,na,na,
Cinpanemab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL,na,na,6ct7:HL:AB,None,None,2018,2019,SNCA,Neurimmune Therapeutics;Biogen,na,Parkinson's disease,na,na,
Citatuzumab,Fab Fusion,G1,Kappa,Phase-I,Active,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM,Viventia Biotech;Sesen Bio,na,Solid tumours,na,na,
Cixutumumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,na,na,None,None,None,2008,2009,IGF1R,Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) ,na,na,Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma,Dyax Human Phage Display,
Claudiximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,na,na,None,None,None,2017,2018,CLDN18,Ganymed Pharmaceuticals,na,Gastric cancer;Oesophageal cancer;Pancreatic cancer;Solid tumours,na,na,Zolbetuximab and Claudiximab are the same mAb
Clazakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,na,na,None,None,None,2012,2013,IL6,Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris,na,Inflammation;Psoriatic arthritis;Renal transplant rejection;Rheumatoid arthritis,Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease,na,
Clervonafusp,di-Fab Fusion,G1,Kappa,Phase-I/II,Active,EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKALIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSRETFGAGTKLELK,na,na,None,None,None,2018,2019,SLC29A2,Valerion Therapeutics,na,Glycogen storage disease type II,na,na,
Clivatuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK,na,na,na,None,None,2009,2010,MUC1,Immunomedics,na,na,Pancreatic cancer,na,
Cobolimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,HAVCR2,AnaptysBio;GlaxoSmithKline;TESARO,na,Non-small cell lung cancer;Solid tumours,na,na,
Codrituzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,na,na,None,None,None,2013,2014,GPC3,Perseus Proteomics;Chugai Pharmaceutical;Roche,na,Liver cancer,na,na,
Cofetuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2017,2018,PTK7,Stemcentrx;Indiana University;Pfizer;Stemcentrx,na,Breast cancer;Solid tumours,na,na,
Coltuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,6ani:HL:IM,None,None,2013,2014,CD19,ImmunoGen,na,Diffuse large B cell lymphoma,Precursor cell lymphoblastic leukaemia-lymphoma,na,
Conatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK,na,na,None,None,None,2008,2009,TNFRSF10B,Amgen;Takeda,na,na,Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours,Abgenix XenoMouse,
Concizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK,na,na,4dtg:HL,None,None,2012,2013,TFPI,Novo Nordisk,na,Haemophilia,na,na,
Coprelotamab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD,1fve:BA:DC/4x4x:AB:CD/6bgt:BA,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,na,ERBB2,TBC,TBC,TBC,TBC,Coprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp have identical V domain.,
Cosfroviximab,Whole mAb,G1,Kappa,Phase-II,Active,DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS,DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR,na,na,None,None,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,
Cosibelimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc,na,Cancer;Lymphoma,na,na,
Crenezumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,5vzx:HL:EI/5vzy:HL,5kmv:HL:EI,None,2011,2012,APP,AC Immune;Genentech;Universidad de Antioquia,na,Alzheimer's disease,na,na,
Crizanlizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,SELP,Selexys Pharmaceuticals;Novartis,Vaso-occlusive crisis,Priapism;Myelofibrosis,na,na,
Crotedumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK,na,na,None,None,None,2015,2016,GCGR,Regeneron Pharmaceuticals;Sanofi,na,na,Type 2 diabetes mellitus,na,
Crovalimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,na,na,5b71:DC:BA,None,None,2018,2019,C5,Chugai Pharmaceutical;Roche,na,Paroxysmal nocturnal haemoglobinuria,na,na,
Cudarolimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK,na,na,None,None,None,2019,na,TNFRSF4,Innovent Biologics,na,Solid tumours,na,na,
Cusatuzumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL,na,na,None,None,None,2017,2018,CD70,arGEN-X,na,Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours;Autoimmune disorders,Nasopharyngeal cancer,POTELLIGENT Technology;SIMPLE Antibody Technology,
Dacetuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,None,None,None,2007,2008,CD40,Seattle Genetics,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma,na,
Daclizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,na,na,3nfs:HL/3nfp:HL:AB,None,None,1994,1998,IL2RA,AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma,Renal transplant rejection,Multiple sclerosis,Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis,GS Gene Expression System,
Dafsolimab,Whole mAb,G2b,Kappa,TBC,Active,QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2020,na,CD3E,TBC,TBC,TBC,TBC,na,
Dalotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,na,na,None,None,None,2009,2010,IGF1R,Pierre Fabre;Merck & Co,na,Breast cancer;Colorectal cancer;Pancreatic cancer,Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours,na,"Jain paper: ""Entries in WHO-INN documents (PL102 and RL64) have errors"""
Dapirolizumab,Fab,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD40LG,Biogen;Biogen Idec;UCB,na,Systemic lupus erythematosus,na,na,
Daratumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,na,na,None,None,None,2009,2010,CD38,Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals,Multiple myeloma,Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours,Non-small cell lung cancer,Medarex HuMAb Mouse,
Datopotamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK,na,na,None,None,None,2019,na,TACSTD2,Daiichi Sankyo,na,Cancers;Non-small cell lung cancer,na,na,
Daxdilimab,Whole mAb,G1,Lambda,Phase-I,Active,QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,na,na,None,None,None,2020,na,LILRA4,Viela Bio,na,Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma,na,na,
Dectrekumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL13,Novartis,na,na,Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis,na,
Demcizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Celgene Corporation;OncoMed Pharmaceuticals,na,na,Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours,na,
Demupitamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,None,5sx4:HL:JI/5sx5:HL:JK,None,2019,na,EGFR,Sinocelltech,na,Cancers,na,na,Likely to be a Panitumumab biosimilar
Denintuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK,na,na,None,None,None,2014,2015,CD19,Seattle Genetics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,
Denosumab,Whole mAb,G2,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,6ghg:HL,2005,2006,TNFSF11,Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network,Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis,Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma,Multiple myeloma ,Abgenix XenoMouse,
Depatuxizumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,Ludwig Institute for Cancer Research;AbbVie,na,na,Solid tumours,na,
Depemokimab,Whole mAb,G1,Kappa,TBC,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,2020,na,IL5,TBC,TBC,TBC,TBC,na,
Derlotuximab,Whole mAb Radiolabelled,G1,Kappa,Approved,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS,ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK,na,na,None,None,None,2015,2016,DNA/H1 Complex,Avid Bioservices;MediPharm Biotech,Lung cancer,Glioblastoma,na,na,
Dezamizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK,na,na,None,None,None,2016,2017,APCS,Pentraxin Therapeutics;GlaxoSmithKline,na,Amyloidosis,na,na,
Dilpacimab,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,None;1bj1:HL:KJ,None;None,None;6bft:HL:AB/1cz8:HL:YX,2018,2019,DLL4;VEGFA,AbbVie,na,Colorectal cancer;Solid tumours,na,na,
Dinutuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL,2013,2014,Ganglioside GD2,National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation,Neuroblastoma,Small cell lung cancer,Malignant melanoma,na,
Diridavumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL,na,na,3gbn:HL/3gbm:HL:IM/5c0s:HL,None,4evn:AB:CD:IJ:OP:KL:EF:GH:MN,2014,2015,Influenza A HA2,National Institute of Allergy and Infectious Diseases;Crucell,na,Influenza A virus infections,na,na,
Disitamab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK,na,na,None,None,None,2018,2019,ERBB2,Yantai Rongchang Biological Engineering,na,Breast cancer;Gastric cancer;Urogenital cancer;Solid tumours,na,na,
Divozilimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS,QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK,na,na,None,None,None,2020,na,MS4A1,TBC,TBC,TBC,TBC,na,
Docaravimab,Whole mAb (Mouse),G2b,Kappa,Phase-I,Active,QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS,DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK,na,na,None,None,None,2019,na,Rabies Virus Strain ERA GP Ectodomain Epitope G-III,Candila Healthcare,na,Rabies post-exposure,na,na,Mouse antibody
Domagrozumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK,na,na,None,5f3h:EF:GH:AB:CD,None,2015,2016,MSTN,Kennedy Krieger Institute;Pfizer,na,Duchenne muscular dystrophy;Limb girdle muscular dystrophies,na,na,
Donanemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK,na,na,None,None,None,2018,2019,APP,Eli Lilly,na,Alzheimer's disease,na,na,
Dostarlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS,DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1,AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Endometrial cancer;Non-small cell lung cancer;Solid tumours,na,na,
Dovanvetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS,EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK,na,na,None,None,None,2019,2020,IL31 (Feline),na,na,na,na,na,
Drozitumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,na,na,4od2:BA,None,None,2010,2011,TNFRSF10B,Genentech,na,na,Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer,na,
Duligotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,na,na,None,None,3p0v:HL:IM/3p0y:HL/3p11:HL,2012,2014,ERBB3,Genentech;Roche,na,na,Solid tumours;Colorectal cancer;Head and neck cancer,na,
Dupilumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,IL4R,Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi,Asthma;Atopic dermatitis,Nasal polyps;Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria;Allergic asthma,na,VelocImmune Mouse,
Durvalumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,na,na,5xj4:HL/5x8m:BC,None,None,2014,2015,CD274,Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine,Non-small cell lung cancer;Urogenital cancer,Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;CNS cancer;Gastrointestinal cancer;Lymphoproliferative disorders;Myelofibrosis;Thyroid cancer;Vulvovaginal cancer,na,Abgenix XenoMouse,
Dusigitumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL,na,na,None,None,None,2012,2013,IGF1&IGF2,MedImmune,na,na,Breast cancer;Liver cancer;Solid tumours,na,
Duvortuxizumab,Bispecific scFv with Crossover,na,Kappa;Lambda,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS,ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2016,2017,CD19;CD3E,Janssen Biotech;MacroGenics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,
Ebronucimab,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL,na,na,None,None,None,2020,na,PCSK9,TBC,TBC,TBC,TBC,na,
Eculizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,5i5k:HL:XY,None,None,2002,2003,C5,Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc,Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria,Neuromyelitis optica;Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection,Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus,GS Gene Expression System,
Edrecolomab,Whole mAb,G2a,Kappa,Approved (w),Discontinued,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,na,na,None,None,None,1995,1996,EPCAM,Ajinomoto;Centocor Inc,Colorectal cancer ,na,Adenocarcinoma;Pancreatic cancer,na,
Efalizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,na,na,3eo9:HL/3eoa:HL:BA/3eob:HL:BA,None,None,2001,2002,ITGAL,Genentech;Merck Serono;XOMA,Psoriasis,na,Psoriatic arthritis;Type 1 diabetes mellitus,na,
Efungumab,scFv,na,Kappa,Phase-III,Discontinued,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,na,na,None,None,None,2006,2007,Heat Shock Protein 90 Homolog,NeuTec Pharma,na,na,Breast cancer;Candidiasis,na,
Eldelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,na,na,None,None,None,2013,2014,CXCL10,Bristol-Myers Squibb;Medarex,na,na,Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries,Medarex UltiMAb Mouse,
Elezanumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL,na,na,None,None,None,2016,2017,RGMA,AbbVie,na,Multiple sclerosis;Spinal cord injuries,na,na,
Elgemtumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK,na,na,None,None,4p59:HL,2014,2015,ERBB3,MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology,na,na,Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours,Medarex HuMAb Mouse,
Elipovimab,Whole mAb,G1,Lambda,Phase-I,Active,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,na,na,None,None,4fq1:HL/4jy4:BA/4fqc:HL,2018,2019,HIV-1 gp120,Gilead Sciences,na,HIV infections,na,na,
Elotuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,SLAMF7,AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma,Multiple myeloma,na,na,na,
Eluvixtamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,CD33;CD3E,TBC,TBC,TBC,TBC,na,
Emactuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK,na,na,4liq:HL,None,None,2014,2015,CSF1R,Roche;University of Texas M. D. Anderson Cancer Center,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours,Giant cell tumour of tendon sheath;Pigmented villonodular synovitis,na,
Emapalumab,Whole mAb,G1,Lambda,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL,na,na,None,None,None,2016,2017,IFNG,NovImmune SA;Swedish Orphan Biovitrum,Haemophagocytic lymphohistiocytosis,na,na,na,
Emerfetamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,CD33;CD3E,TBC,TBC,TBC,TBC,na,
Emicizumab,Bispecific mAb,G4;G4,Kappa;Kappa,Approved,NFD,QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,F9;F10,Chugai Pharmaceutical;Roche,Haemophilia A,na,na,na,
Emibetuzumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,MET,Eli Lilly,na,Gastric cancer;Non-small cell lung cancer;Cancer,na,na,
Enapotamab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,AXL,Genmab,na,Solid tumours,na,na,
Enavatuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK,na,na,None,None,None,2010,2011,TNFRSF12A,PDL BioPharma;Abbott Laboratories,na,na,Solid tumours,na,
Encelimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3,Anaptys Bio;TESARO,na,Solid tumours,na,na,
Enfortumab,Whole mAb ADC,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,PVRL4,Agensys;Seattle Genetics,na,Urogenital cancer,na,na,
Enibarcimab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK,na,na,None,None,None,2020,na,ADM,TBC,TBC,TBC,TBC,na,
Enoblituzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,na,na,None,None,None,2015,2017,CD276,MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Prostate cancer;Solid tumours;Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer,na,na,
Enokizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,IL9,Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune,na,na,Asthma,na,
Enoticumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,VelocImmune Mouse,
Ensituximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS,QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK,na,na,None,None,None,2010,2011,MUC5AC,Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine,na,Colorectal cancer;Pancreatic cancer,na,na,
Envafolimab,Single Domain Variable Fragment;H,G1,na,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSS,na,na,na,None,None,None,2018,2019,PDL1,Alphamab;3D Medicines;Sun Yat-Sen University,na,Biliary cancer;Breast cancer;Solid tumours,na,na,
Epcoritamab,Bispecific mAb,G1,Lambda;Kappa,Phase-I/II,Active,EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL,EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,None;None,None;None,None;3giz:HL,2019,2020,CD3E;MS4A1,Genmab,na,Haematological malignancies,na,na,Second Fv closely related to Ofatumumab
Epratuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,na,na,None,5vkk:AB:HL/5vl3:EF:AB:HL:CD,None,1999,2000,CD22,Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB,na,na,Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia,na,
Eptinezumab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS,QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK,na,na,None,None,None,2016,2017,CALCA&CALCB,Alder Biopharmaceuticals,na,Migraine,na,na,
Erenumab,Whole mAb,G2,Lambda,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,na,na,6umh:HL/6umi:HL/6umj:HL,None,None,2016,2017,CALCRL,Amgen;Novartis,Migraine,na,Hot flashes,Abgenix XenoMouse,
Etaracizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,ITGAV_ITGB3,Applied Molecular Evolution;MedImmune,na,na,Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis,na,
Etevritamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS,DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,EGFR;CD3E,TBC,TBC,TBC,TBC,na,
Etigilimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,TIGIT,OncoMed Pharmaceuticals,na,Solid tumours,na,na,
Etokimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,IL13,AnaptysBio,na,Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis,na,na,
Etrolizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,na,na,None,None,None,2010,2011,ITGA4_ITGB7&ITGAE_ITGB7,Genentech;Roche,na,Crohn's disease;Ulcerative colitis,na,na,
Evinacumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK,na,na,None,None,None,2014,2015,ANGPTL3,Regeneron Pharmaceuticals;Sanofi,na,Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Hypertriglyceridaemia,na,na,
Evolocumab,Whole mAb,G2,Lambda,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,na,na,None,None,None,2012,2013,PCSK9,Amgen;Amgen Astellas BioPharma;University Hospital Inselspital,Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke,Hyperlipidaemia,na,Abgenix XenoMouse,
Ezabenlimab,Whole mAb,G4,Kappa,Phase-I,Active,EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNYNYYAMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPQTFGQGTKLEIK,na,na,None,None,None,2019,na,PDCD1,Boehringer Ingelheim,na,Cancers;Non-small cell lung cancer;Solid tumours;Lymphoma,na,na,
Faricimab,Bispecific mAb,G1,Kappa;Lambda,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL,1cz8:HL:YX;None,None;None,1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC,2017,2018,VEGFA;ANGPT2,Chugai Pharmaceutical;Roche,na,Diabetic macular oedema;Wet age-related macular degeneration,na,Dual-Affinity Re-Targeting Technology,
Farletuzumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,na,na,None,None,None,2008,2009,FOLR1,Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd,na,Ovarian cancer;Non-small cell lung cancer,Solid tumours,na,
Fasinumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,NGFB,Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi,na,Back pain;Pain,na,VelocImmune Mouse,
Feladilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK,na,na,None,None,None,2019,na,ICOS,GlaxoSmithKline,na,Solid tumours,na,na,
Felzartamab,Whole mAb,G1,Lambda,Phase-I/II,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL,na,na,None,None,None,2019,na,CD38,MorphoSys,na,Multiple myeloma,na,na,
Fezakinumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,na,na,None,None,None,2009,2010,IL22,Pfizer;Wyeth,na,na,Psoriasis;Rheumatoid arthritis,na,
Fianlimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3,Regeneron Pharmaceuticals,na,Cancer,na,na,
Fibatuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK,na,na,None,None,None,2015,2017,EPHA3,Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma,na,POTELLIGENT Technology;Humaneering Technology,Fibatuzumab and Ifabotuzumab are the same mAb
Ficlatuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,HGF,AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco,na,Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer,Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma,na,
Figitumumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,na,na,None,None,None,2008,2009,IGF1R,Pfizer,na,na,Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours,na,
Firivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK,na,na,None,None,None,2014,2015,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,na,Firivumab and Navivumab are the same mAb
Flanvotumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK,na,na,None,None,None,2011,2012,TYRP1,ImClone Systems;Eli Lilly,na,na,Malignant melanoma,na,
Fletikumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2013,2014,IL20,ZymoGenetics;Novo Nordisk,na,na,Psoriasis;Rheumatoid arthritis,na,
Flotetuzumab,Bispecific scFv with Crossover,na,Kappa;Lambda,Phase-I/II,Active,EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,CD3E;IL3RA,MacroGenics;Servier,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,na,Dual-Affinity Re-Targeting Technology,
Fontolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK,na,na,None,1t3f:BA/1t04:DC:BA,None,2002,2003,IFNG,PDL BioPharma,na,na,Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis,na,
Foralumab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,CD3E,Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences,na,Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus,Transplant rejection;Type 1 diabetes mellitus,na,
Foravirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK,na,na,None,None,None,2008,2009,RV Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,
Fremanezumab,Whole mAb,G2,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,CALCA&CALCB,Rinat Neuroscience;Teva Pharmaceutical Industries,Migraine,Headache,Cluster headache,na,
Fresolimumab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,na,na,None,3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG,None,2009,2010,TGFB,Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme,na,Osteogenesis imperfecta,Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis,CAT Phage Display,
Frovocimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK,na,na,None,None,None,2018,2019,PCSK9,Eli Lilly,na,Hypercholesterolaemia,na,na,
Frunevetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA,DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Feline osteoarthritis,na,PETization Technology,
Fulranumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,4m6o:HL,None,2010,2011,NGFB,Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen,na,na,Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain,Abgenix XenoMouse,
Futuximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK,na,na,None,None,None,2012,2013,EGFR,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,na,Futuximab and Zatuximab are the same mAb
Galcanezumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK,na,na,None,None,None,2015,2016,CALCA&CALCB,Eli Lilly,Migraine,Cluster headache,Musculoskeletal pain,na,
Galiximab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,na,na,None,None,None,2003,2004,CD80,Biogen;Biogen Idec,na,na,Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis,na,
Gancotamab,scFv,na,Lambda,Phase-II,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,None,None,None,2018,2019,ERBB2,Merrimack Pharmaceuticals;HERMES BioSciences,na,na,Breast cancer,na,
Ganitumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,na,na,None,None,None,2010,2011,IGF1R,Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center,na,Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma,Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer,na,
Gantenerumab,Whole mAb,G1,Kappa,Phase-III,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,na,na,5csz:HL:AB,None,None,2012,2008,APP,MorphoSys;Chugai Pharmaceutical;Roche,na,Alzheimer's disease,na,na,
Garadacimab,Whole mAb,G4,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL,na,na,None,None,None,2018,2019,F12,CSL Behring,na,Hereditary angioedema,na,na,
Garetosmab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,INHBA,Regeneron Pharmaceuticals,na,Fibrodysplasia ossificans progressiva;Musculoskeletal disorders,na,na,
Garivulimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK,na,na,None,None,None,2020,na,CD274,TBC,TBC,TBC,TBC,na,
Gatipotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS,DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK,na,na,None,None,None,2016,2017,MUC1,NEMOD Biotherapeutics;Glycotope,na,Ovarian cancer;Solid tumours,na,GlycoExpress Technology,Gatipotuzumab and PankoMab are the same mAb
Gatralimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK,na,na,6obd:HL,None,None,2019,2020,CD52,Sanofi,na,na,Multiple sclerosis,na,
Gedivumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS,EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK,na,na,None,None,4kvn:HL,2016,2017,Influenza A HA,Genentech,na,Influenza A virus infections,na,na,
Gemtuzumab,Whole mAb ADC,G4,Kappa,Approved,NFD,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,na,na,na,na,na,2016,2017,CD33,UCB;Celgene Corporation;Pfizer;University of California San Diego,Acute myeloid leukaemia,na,na,na,
Geptanolimab,Whole mAb,G4,Kappa,TBC,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK,na,na,None,None,None,2020,na,PDCD1,TBC,TBC,TBC,TBC,na,
Gevokizumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,na,na,4g6k:HL/4g6m:HL,None,None,2010,2011,IL1B,IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA,na,Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma,Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma,na,
Giloralimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK,na,na,None,None,None,2019,na,CD40,AbbVie,na,Solid tumours,na,na,
Gilvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS,DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK,na,na,na,na,na,2016,2017,PDCD1 (Canine),Merck,na,Canine Cancers,na,na,
Gimsilumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS,EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK,na,na,None,None,None,2017,2018,CSF2,Ludwig Institute for Cancer Research;Morphotek,na,na,Cancer;Rheumatoid arthritis,MORPHODOMA Technology,
Girentuximab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,na,na,None,None,None,2009,2010,CA9,Centocor Inc;Heidelberg Pharma AG,na,na,Renal cancer,na,
Glembatumumab,Whole mAb ADC,G2,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,na,na,None,None,None,2015,2016,GPNMB,CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA),na,na,Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma,na,
Glenzocimab,Fab,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGRDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT,na,na,None,None,None,2018,2019,GP6,Acticor Biotech,na,Stroke,na,na,
Glofitamab,Bispecific mAb with Domain Crossover,G1,Lambda;Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,None;3pp3:HL/3pp4:HL,None;None,None;None,2019,2020,CD3E;MS4A1,Roche,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma,na,na,
Golimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,5yoy:RO:IF:QN:GD:HE:PM,None,None,2004,2005,TNFA,Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex,Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,Hearing disorders;Type 1 diabetes mellitus,Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis,Medarex UltiMAb Mouse,
Gomiliximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,na,na,None,3fzu:HL:CD,None,2004,2004,FCER2,Biogen Idec,na,na,Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia,na,Lumiliximab and Gomiliximab are the same mAb
Gontivimab,Bispecific Single Domains (VH-VH'-VH’),na,na,Phase-II,Discontinued,DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,None;None,None;None,None;None,2019,na,RSV gpF,Ablynx,na,na,Respiratory syncytial virus infections,na,
Gosuranemab,Whole mAb,G4,Kappa,Phase-II,Active,EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK,na,na,None,None,None,2018,2019,MAPT,Biogen;Bristol-Myers Squibb;iPierian,na,Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders,Cardiovascular disorders;Metabolic disorders,na,
Gremubamab,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYCLQDYNYPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK,None;None,None;None,None;None,2019,2020,PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas),MedImmune,na,Nosocomial pneumonia,na,na,
Grisnilimab,Whole mAb,G2a,Lambda,TBC,Active,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL,na,na,None,None,None,2020,na,CD7,TBC,TBC,TBC,TBC,na,
Guselkumab,Whole mAb,G1,Lambda,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,na,na,4m6m:HL/4m6n:HL,None,None,2013,2014,IL23A,Janssen Biotech;MorphoSys;Taiho Pharmaceutical,Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis ,Crohn's disease;Hidradenitis suppurativa;Rheumatoid arthritis;Ulcerative colitis;Familial adenomatous polyposis,na,MorphoSys HuCAL Phage Display,
Ianalumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYQWVPKIGVFDSWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQFILPEYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFYSSPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,TNFRSF13C,H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis,na,Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia,na,POTELLIGENT Technology,
Ibalizumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,na,na,3o2d:HL,None,None,2007,2008,CD4,Biogen Idec;TaiMed Biologics;Theratechnologies,HIV-1 infections,na,na,na,
Icatolimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK,na,na,None,None,None,2019,na,BTLA,Shanghai Junshi Biosciences,na,Solid tumours,na,na,Chimeric
Icrucumab,Whole mAb,G1,Kappa,Phase-II,Active,QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,FLT1,ImClone Systems,na,Breast cancer,Colorectal cancer;Urogenital cancer,na,
Idactamab,Whole mAb,G1,Kappa,TBC,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK,na,na,None,None,None,2020,na,SLC1A5,TBC,TBC,TBC,TBC,na,
Idarucizumab,Fab,G1,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK,na,na,4jn2:HL:BA/4jn1:HL,None,None,2013,2014,Dabigatran,Boehringer Ingelheim,Blood coagulation disorders,na,na,na,
Ieramilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,CD223,Immutep Limited;Novartis,na,Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours,na,na,
Ifabotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK,na,na,None,None,None,2015,2017,EPHA3,Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma,na,POTELLIGENT Technology;Humaneering Technology,Fibatuzumab and Ifabotuzumab are the same mAb
Iladatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2017,2019,CD79B,Roche,na,na,Non-Hodgkin's lymphoma,na,
Imalumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK,na,na,6foe:HL:AB,None,None,2014,2015,MIF,Cytokine PharmaSciences;Baxalta;Shire;Takeda,na,Colorectal cancer;Malignant ascites,Solid tumours;Lupus nephritis,na,
Imaprelimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK,na,na,None,None,None,2017,2018,MCAM,Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation,na,na,Cancer;Inflammation;Psoriasis,na,
Imgatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,na,na,None,None,None,2012,2013,EGFR,GLYCART Biotechnology;Roche,na,na,Colorectal cancer;Head and neck cancer;Non-small cell lung cancer,GlycoMAb Technology,
Inclacumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,SELP,Genmab;Roche;Global Blood Therapeutics,na,na,Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders,Medarex UltiMAb Mouse,
Indatuximab,Whole mAb ADC,G4,Kappa,Phase-II,Active,QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS,DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK,na,na,None,None,None,2011,2012,SDC1,Biotest AG,na,Bladder cancer;Breast cancer;Multiple myeloma,na,na,
Indusatumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK,na,na,None,None,None,2014,2015,GUCY2C,Millennium;Takeda Oncology,na,na,Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer,na,
Inebilizumab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD19,Cellective Therapeutics;MedImmune,na,Neuromyelitis optica;Chronic lymphocytic leukaemia;B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Autoimmune disorders;Myasthenia gravis;Renal transplant rejection, Systemic scleroderma;Diffuse large B cell lymphoma,POTELLIGENT Technology,
Infliximab,Whole mAb,G1,Kappa,Approved,NFD,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,na,na,5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB,None,None,1997,1998,TNFA,Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,na,Berylliosis;Hepatitis C;Pyoderma,na,
Inotuzumab,Whole mAb ADC,G4,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2004,2005,CD22,Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group,Precursor cell lymphoblastic leukaemia-lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia,Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,na,
Intetumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,None,None,None,2009,2010,ITGAV_ITGB3,Centocor Inc;Janssen Biotech;Janssen-Cilag,na,na,Malignant melanoma;Prostate cancer,VelocImmune Mouse,
Ipilimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL,None,None,2005,2006,CTLA4,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center,Malignant melanoma;Renal cell carcinoma,Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma,HIV infections;Lymphoma,Medarex UltiMAb Mouse,
Iratumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS,DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK,na,na,None,None,None,2005,2006,TNFRSF8,Medarex,na,na,Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma,Medarex UltiMAb Mouse,
Isatuximab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS,DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK,na,na,4cmh:BC,None,None,2014,2015,CD38,ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi,na,Multiple myeloma;Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Non-small cell lung cancer;Peripheral T-cell lymphoma;Prostate cancer;Solid tumours;Urogenital cancer,na,na,
Iscalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2017,2018,CD40,Novartis;XOMA,na,Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus,Rheumatoid arthritis,na,
Isecarosmab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-I,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS,na,EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2019,na,ADAMTSL5;ALB,Merck,na,Solid tumours,na,na,
Istiratumab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II,Discontinued,EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK,QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL,None;None,None;None,None;None,2017,2018,IGF1R;ERBB3,Adimab;Merrimack Pharmaceuticals,na,na,Ovarian cancer;Pancreatic cancer;Solid tumours,na,
Itepekimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK,na,na,None,None,None,2019,na,IL33,Regeneron Pharmaceuticals;Sanofi,na,Asthma;COPD,na,na,
Itolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK,na,na,None,None,None,2010,2011,CD6,Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium,Plaque psoriasis,Rheumatoid arthritis;Graft-versus-host disease,Autoimmune disorders;Multiple sclerosis;Psoriasis,na,
Ivuxolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4,Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California,na,Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma,na,na,
Ixekizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,na,na,6nov:AB,6nou:AA,None,2011,2012,IL17A,Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis,na,na,
Izuralimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,None;None,2020,na,ICOS;PDCD1,TBC,TBC,TBC,TBC,na,
Labetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK,na,na,None,None,None,2015,2016,CEACAM5,Immunomedics,na,Colorectal cancer,na,na,
Lacnotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS,DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK,na,na,None,None,None,2016,2017,CSF1,Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital,na,Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours,Bone metastases;Prostate cancer,na,
Lacutamab,Whole mAb,G1,Kappa,Phase-II,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,KIR3DL2,University of Genoa;Innate Pharma,na,Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome,na,na,
Ladiratuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK,na,na,None,None,None,2017,2018,SLC39A6,Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics,na,Breast cancer,na,na,
Lambrolizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,na,na,5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC,None,None,2013,2014,PDCD1,Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society,Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma,Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections,na,na,Pembrolizumab and Lambrolizumab are the same mAb
Lampalizumab,Fab,G1,Kappa,Phase-III,Discontinued,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,na,na,4d9q:HL:ED/4d9r:HL:ED,None,None,2012,2013,CFD,Tanox;Genentech,na,na,Dry age-related macular degeneration,na,
Lanadelumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK,na,na,4pub:HL/4ogy:HL:MN/4ogx:HL,None,None,2015,2016,KLKB1,Dyax;Shire;Takeda,Hereditary angioedema,na,Diabetic macular oedema,na,
Landogrozumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Eli Lilly,na,Cachexia;Muscular atrophy;Pancreatic cancer,Cancer,na,
Laprituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK,na,na,None,None,None,2015,2016,EGFR,ImmunoGen,na,na,Solid tumours,na,
Larcaviximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK,na,na,None,None,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,
Lebrikizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,na,na,4i77:HL,None,None,2009,2010,IL13,Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox,na,Atopic dermatitis,Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis,na,
Lecanemab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS,DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNFRSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK,na,na,None,None,None,2019,na,APP,Biogen;Eisai,na,Dementia;Alzheimers,na,na,
Lenvervimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS,DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK,na,na,None,None,None,2017,2018,HBV,Green Cross;GC Pharma;AbbVie,na,Hepatitis B,na,na,
Lenzilumab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,CSF2,Humanigen;KaloBios Pharmaceuticals,na,Drug hypersensitivity;Chronic myelomonocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Solid tumours,Asthma;Rheumatoid arthritis,Humaneering Technology,
Leronlimab,Whole mAb,G4,Kappa,Preregistration,Active,EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,CCR5,CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute,na,HIV infections;HIV-1 infections;Graft-versus-host disease;Breast cancer;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer,na,na,
Lesofavumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,Influenza B Virus,Genentech,na,na,Influenza B virus infections,na,
Letaplimab,Whole mAb,G4,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,na,na,None,None,None,2020,na,CD47,TBC,TBC,TBC,TBC,na,
Letolizumab,Single Domain Variable Fragment;H,G1,na,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS,na,na,na,None,None,None,2016,2017,CD40LG,Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute,na,Graft-versus-host disease;Idiopathic thrombocytopenic purpura,na,na,
Levilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS,DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,IL6R,Biocad,na,Rheumatoid arthritis,Autoimmune disorders,na,
Lexatumumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,na,na,None,None,4od2:BA,2006,2007,TNFRSF10B,Cambridge Antibody Technology;Human Genome Sciences,na,na,Solid tumours,na,
Lifastuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK,na,na,None,None,None,2013,2014,SLC34A2,Genentech,na,na,Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer,na,
Ligelizumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK,na,na,6uqr:AC,None,None,2012,2013,IGHE,Novartis;Tanox,na,Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid,Hypersensitivity,na,
Lilotomab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS,DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK,na,na,None,None,None,2014,2015,CD37,Nordic Nanovector,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,na,
Lintuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,1996,1997,CD33,PDL BioPharma;Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,
Lirilumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,na,na,None,None,None,2012,2013,KIRD2,Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center,na,Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer;Haematological malignancies;Multiple myeloma;Lymphoma,Acute myeloid leukaemia;Hepatitis C,Medarex UltiMAb Mouse,
Lodapolimab,Whole mAb,G1,Lambda,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,na,na,None,None,None,2019,2020,PDL1,Dana-Farber Cancer Institute;Eli Lilly,na,Solid tumours,na,na,
Lodelcizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS,QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Novartis,na,na,Hypercholesterolaemia,na,
Lokivetmab,Canine Whole mAb,G2,Kappa,Approved,NFD,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL31,Zoetis,Canine atopic dermatitis,na,na,na,
Loncastuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,6ani:HL:IM,None,2017,2018,CD19,ADC Therapeutics,na,Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma,na,
Lorukafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL,2018,2019,Ganglioside GD2,Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison,na,Malignant melanoma;Neuroblastoma,na,na,
Lorvotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK,na,na,None,None,None,2010,2011,NCAM1,ImmunoGen,na,Haematological malignancies,Multiple myeloma;Solid tumours;Small cell lung cancer,na,
Losatuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,AbbVie,na,Solid tumours,na,na,Losatuxizumab and Serclutamab have identical variable domains
Lucatumumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2007,2008,CD40,Novartis;XOMA,na,na,Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma,na,
Lulizumab,Single Domain Variable Fragment;L,na,Kappa,Phase-II,Active,na,DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK,na,na,None,None,None,2014,2015,CD28,Bristol-Myers Squibb,na,Sjogren's syndrome;Systemic lupus erythematosus,na,na,
Lumiliximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,na,na,None,3fzu:HL:CD,None,2004,2004,FCER2,Biogen Idec,na,na,Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia,na,Lumiliximab and Gomiliximab are the same mAb
Lumretuzumab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK,na,na,4leo:AB,None,None,2014,2015,ERBB3,Roche,na,Non-small cell lung cancer,Breast cancer;Solid tumours,GlycoMAb Technology,
Lupartumab,Whole mAb ADC,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS,ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL,na,na,None,None,None,2016,2017,LYPD3,Bayer HealthCare,na,Solid tumours,na,na,
Lutikizumab,Bispecific Dual Variable Domain IG,G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,None;None,None;None,None;None,2016,2017,IL1A;IL1B,Abbott Laboratories;AbbVie,na,na,Osteoarthritis,Dual Variable Domain Immunoglobulin Technology,
Maftivimab,Whole mAb,G1,Kappa,Preregistration,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK,na,na,None,None,None,2018,2019,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,na,na,Ebola virus infections,na,
Magrolimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK,na,na,None,5iwl:AA:BB,None,2018,2019,CD47,Forty Seven;Merck KGaA;Stanford University,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer,Lymphoma,na,
Manelimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Biocad,na,Solid tumours;Cancer,na,na,
Margetuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,ERBB2,Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme,na,Breast cancer;Gastric cancer,Bladder cancer;Non-small cell lung cancer;Ovarian cancer,na,
Marstacimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL,na,na,None,None,None,2013,2014,ERBB2,Pfizer,na,Haemophilia,na,na,
Matuzumab,Whole mAb,G1,nd,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,na,na,3c08:HL/5vr9:HL:AB,5vsi:HL/3c09:HL:CB,None,2003,2003,EGFR,ImClone Systems;Merck KGaA;Takeda,na,na,Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer,na,
Mavezelimab,Whole mAb,G4,Kappa,Phase-II,Active,QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK,na,na,None,None,None,2019,na,LAG3,Merck,na,Non-small cell lung cancer;Haematological malignancies;Solid tumours,na,na,
Mavrilimumab,Whole mAb,G4,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,na,na,None,None,None,2009,2010,CSF2RA,Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune,na,Giant cell arteritis,Rheumatoid arthritis,CAT Phage Display,
Melrilimab,Whole mAb,G2,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK,na,na,None,None,None,2020,na,IL1RL1,TBC,TBC,TBC,TBC,na,
Mepolizumab,Whole mAb,G1,Kappa,Approved,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,1999,2000,IL5,GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases,Asthma;Churg-Strauss syndrome,Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Atopic dermatitis;Eosinophilic oesophagitis,na,na,
Mezagitamab,Whole mAb,G1,Lambda,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL,na,na,None,None,None,2019,2020,CD38,Takeda,na,Multiple myeloma;Systemic lupus erythematosus,Rheumatoid arthritis,na,
Milatuzumab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK,na,na,None,None,None,2007,2008,CD74,Immunomedics,na,Systemic lupus erythematosus,Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma,na,
Mipasetamab,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK,na,na,None,None,None,2020,na,AXL,TBC,TBC,TBC,TBC,na,
Miptenalimab,Whole mAb,G4,Kappa,Phase-I,Active,QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK,na,na,None,None,None,2019,na,LAG3,Boehringer Ingelheim,na,Solid tumours;Lymphoma,na,na,
Mirikizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL23A,Eli Lilly,na,Plaque psoriasis;Ulcerative colitis;Crohn's disease,na,na,
Miromavimab,Whole mAb (Mouse),G1,Kappa,Unknown,Active,QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK,na,na,None,None,None,2019,na,Rabies Virus Strain ERA GP Ectodomain Epitope G-II,Candila Healthcare,na,Rabies post-exposure,na,na,
Mirvetuximab,Whole mAb ADC,G1,Kappa,Phase-III,Active,QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS,DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK,na,na,None,None,None,2015,2016,FOLR1,ImmunoGen;National Comprehensive Cancer Network,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Breast cancer;Endometrial cancer;Solid tumours,na,na,
Mirzotamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK,na,na,None,None,None,2019,na,CD276,AbbVie,na,Haematological malignancies;Solid tumours,na,na,
Mitazalimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL,na,na,None,None,None,2017,2019,CD40,Alligator Bioscience;Janssen Biotech,na,Solid tumours,na,na,Mitazalimab and Vanalimab are the same mAb
Modakafusp,Whole mAb Fusion,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK,na,na,None,None,None,2019,na,ADPRC,Takeda,na,Multiple myeloma,na,na,
Modotuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK,na,na,None,None,None,2012,2014,EGFR,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,na,
Mogamulizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CCR4,Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical,Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome,Spinal cord disorders;Solid tumours,Non-small cell lung cancer;Asthma;Hypersensitivity,POTELLIGENT Technology,
Monalizumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK,na,na,None,None,None,2015,2016,KLRC1,Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk,na,Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies,Inflammation;Rheumatoid arthritis,na,
Mosunetuzumab,Bispecific mAb,G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,None;None,None;None,None;4k7p:YX,2017,2018,CD3E;MS4A1,Genentech,na,Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma,na,na,
Motavizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,na,na,3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC,5k8a:BA:FE:VM:HL/4jlr:AB:HL,None,2006,2007,RSV gpF,MedImmune,na,na,Respiratory syncytial virus infections,Affinity Matured from Palivizumab,
Moxetumomab,Fv Fusion,na,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI,na,na,None,None,None,2009,2010,CD22,National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA),Hairy cell leukaemia,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,CAT Phage Display,
Murlentamab,Whole mAb,G1,Kappa,Phase-II,Active,QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,AMHR2,LFB Biotechnologies;GamaMabs Pharma,na,Colorectal cancer;Gynaecological cancer,na,na,
Muromonab,Whole mAb,G2a,Kappa,Approved,Discontinued,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,na,na,1sy6:HL,None,None,1988,1989,CD3E,Cancer Research UK;Ortho-McNeil;XOMA,na,na,Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis,na,Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.
Namilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK,na,na,None,None,None,2010,2011,CSF2,Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH,na,Ankylosing spondylitis,Plaque psoriasis;Rheumatoid arthritis,Human Phage Display,
Naptumomab,Fab Fusion,G1,Kappa,Phase-III,Discontinued,EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS,SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK,na,na,None,None,None,2006,2007,TPBG,Active Biotech,na,na,Non-small cell lung cancer;Pancreatic cancer;Renal cancer,na,
Naratuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS,DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK,na,na,None,None,None,2015,2016,CD37,ImmunoGen;Chronic lymphocytic leukaemia,na,Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,Chronic lymphocytic leukaemia,na,
Narnatumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,MST1R,ImClone Systems;Eli Lilly;ImClone Systems,na,na,Solid tumours,na,
Narsoplimab,Whole mAb,G4,Lambda,Preregistration,Active,QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS,QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,na,na,None,None,None,2019,2020,MASP2,Omeros,na,Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis,Stroke;Wet age-related macular degeneration,na,
Natalizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,na,na,None,4irz:HL,None,1998,1999,ITGA4,Biogen;Biogen Idec;Elan Corporation;Perrigo,Crohn's disease;Multiple sclerosis,Epilepsy;Graft-versus-host disease;Stroke,Multiple myeloma;Rheumatoid arthritis,na,
Navivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS,EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK,na,na,4r8w:HL,6fg1:HL/6fg2:HL,None,2015,2016,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,na,
Navicixizumab,Bispecific mAb,G2,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,DLL4;VEGFA,OncoMed Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours,Colorectal cancer,na,
Naxitamab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,na,na,None,None,None,2018,2019,Ganglioside GD2,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,na,Neuroblastoma;Osteosarcoma,Breast cancer;Sarcoma;Small cell lung cancer,na,
Necitumumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,na,na,6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL,None,None,2008,2009,EGFR,ImClone Systems;Eli Lilly,Non-small cell lung cancer,Solid tumours,Colorectal cancer,na,
Nemolizumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,IL31RA,Chugai Pharmaceutical;Galderma;Maruho,na,Atopic dermatitis;Prurigo nodularis;Pruritus,na,na,
Nesvacumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK,na,na,None,None,None,2012,2013,ANGPT2,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,na,
Netakimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK,na,na,na,None,None,2017,2018,IL17A,CJSC Biocad,Plaque psoriasis,Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis,na,na,
Nidanilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL1RAP,Lund University;Cantargia,na,Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer;Solid tumours,na,na,
Nimacimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK,na,na,None,None,None,2018,2019,CNR1,Bird Rock Bio,na,Diabetic nephropathies;Diabetic gastroparesis;Non-alcoholic fatty liver disease;Obesity;Non-alcoholic steatohepatitis,Non-alcoholic steatohepatitis,na,
Nimotuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,na,na,None,3gkw:HL,None,2005,2006,EGFR,Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience,Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer,Cervical cancer;Gastric cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer,,na,
Nipocalimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL,na,na,None,None,5whk:HL/5whj:HL,2019,na,FCGRT,Momenta,na,Autoimmune diseases,na,na,
Nirsevimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK,na,na,5udc:HL:BC:EG,None,4jha:HL/4jhw:HL,2018,2019,RSV,AIMM Therapeutics;MedImmune,na,Respiratory syncytial virus infections,na,na,
Nivolumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,na,na,5ggq:HL/5wt9:HL/5ggr:HL:AB,None,None,2012,2013,PDCD1,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics,Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer,Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Chronic myeloid leukaemia;Glioma;Hepatitis C;Sepsis,na,Medarex UltiMAb Mouse,
Nurulimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,5xj3:AB/5tru:HL/6jc2:HL,None,2019,2020,CTLA4,Biocad,na,Malignant melanoma,na,na,Likely to be an Ipilimumab Biosimilar
Obexelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,Xencor,na,Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus,na,XmAb Antibody Engineering Technology,
Obiltoxaximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR,na,na,None,None,None,2015,2016,Anthrax Protective Antigen,Elusys Therapeutics,Anthrax,na,na,na,
Obinutuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,na,na,3pp3:HL:IK/3pp4:HL,None,None,2008,2011,MS4A1,GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds,Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia,Primary biliary cirrhosis,GlycoMAb Technology,Obinutuzumab and Afutuzumab are the same mAb
Obrindatamab,Bispecific scFv with Domain Crossover,,Kappa;Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,CD276;CD3E,TBC,TBC,TBC,TBC,na,
Ocaratuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,MS4A1,Applied Molecular Evolution;MENTRIK Biotech,na,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis,na,
Ociperlimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCASSGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2020,na,TIGIT,TBC,TBC,TBC,TBC,na,
Ocrelizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,na,na,None,None,4k7p:YX,2005,2006,MS4A1,Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche,Multiple sclerosis,na,Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus,na,
Odesivimab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,na,Ebola virus infections ,na,na,
Odronextamab,Bispecific mAb,G4,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,None;None,None;None,None;None,2019,2020,MS4A1;CD3E,Regeneron Pharmaceuticals,na,Follicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,na,
Ofatumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,na,na,3giz:HL,None,None,2005,2006,MS4A1,Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network,Chronic lymphocytic leukaemia,B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia,Medarex HuMAb Mouse,
Olaratumab,Whole mAb,G1,Kappa,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,na,na,None,None,None,2010,2011,PDGFRA,ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research,Soft tissue sarcoma,Pancreatic cancer;Solid tumours,Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer,Medarex UltiMAb Mouse,
Oleclumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL,na,na,None,None,None,2016,2017,NT5E,MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute,na,Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours,na,na,
Olendalizumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK,na,na,None,None,None,2015,2017,C5,Alexion Pharmaceuticals,na,Antiphospholipid syndrome;Graft-versus-host disease,Inflammation,na,
Olinvacimab,Whole mAb,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS,NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL,na,na,None,None,None,2018,2019,KDR,PharmAbcine;3SBio,na,Glioblastoma;Breast cancer,Cancer;Choroidal neovascularisation;Solid tumours,na,Olinvacimab and Tanibirumab are the same mAb
Olokizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,na,na,4cni:HL:AB,None,None,2010,2011,IL6,R-Pharm;UCB,na,Rheumatoid arthritis,na,na,
Omalizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,na,na,4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL,5g64:IM:HL,None,2000,2001,IGHE,Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis,Allergic asthma;Urticaria,Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis,Hypersensitivity;Peanut hypersensitivity,na,HC IMGT 71 is V not L as in Jain paper
Omburtamab,Whole mAb Radiolabelled,G1,Kappa,Phase-II/III,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK,na,na,5cma:BA,None,None,2018,2019,CD276,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,na,Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma,Peritoneal cancer;Solid tumours,na,
Omodenbamab,Whole mAb,G3,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK,na,na,None,None,None,2020,na,SpA,TBC,TBC,TBC,TBC,na,
Onartuzumab,Fab + di-Fc,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,na,na,4k3j:HL,None,None,2010,2011,MET,Chugai Pharmaceutical;Genentech,na,na,Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours,na,
Onfekafusp,Whole mAb Fusion,na,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,Haematological malignancies;Hodgkin's disease,Brain cancer;Non-small cell lung cancer;Solid tumours,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Ongericimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK,na,na,None,None,None,2019,na,PCSK9,Shanghai Junshi Biosciences,na,Hypercholesterolemia,na,na,
Ontamalimab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK,na,na,4hcr:MN:HL,None,None,2018,2019,MADCAM1,Pfizer;Takeda,na,Crohn's disease;Ulcerative colitis,na,na,
Ontuxizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK,na,na,None,None,None,2013,2014,CD248,Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA),na,Colorectal cancer;Malignant melanoma;Soft tissue sarcoma;Lymphoma;Solid tumours,na,na,
Onvatilimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK,na,na,None,None,None,2017,2018,VSIR,Janssen Research & Development,na,na,Solid tumours,na,
Opicinumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS,DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK,na,na,4oqt:HL,None,None,2015,2106,LINGO1,Biogen Idec;Dyax;Biogen,na,Multiple sclerosis;Optic neuritis,na,Dyax Human Phage Display,
Oportuzumab,scFv,na,Kappa,Preregistration,Active,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM,University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies,na,Bladder cancer;Head and neck cancer,Liver cancer;Ovarian cancer,na,
Opucolimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS,QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVLSQPKAAPSVTL,na,na,None,None,None,2019,na,PDL1,Shanghai Henlius Biotech,na,Solid tumours,na,na,
Orilanolimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK,na,na,6nha:HL,None,None,2018,2019,FCGRT,Syntimmune,na,Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus,na,na,
Orticumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL,na,na,None,None,None,2012,2013,OxLDL,Abcentra;BioInvent International;Genentech,na,Atherosclerosis;Psoriasis,na,Human Phage Display,
Osocimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK,na,na,None,6hhc:HL,None,2018,2019,F11,Bayer HealthCare,na,Venous thromboembolism,Arterial thrombosis;Venous thrombosis,na,
Otelixizumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,na,na,None,None,None,2007,2008,CD3E,BTG;GlaxoSmithKline;Tolerx,na,Type 1 diabetes mellitus,Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis,na,
Otilimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL,na,na,None,5c7x:MN:HL/5d7s:HL,5d72:MN:HL/5d71:HL,2018,2019,CSF2,GlaxoSmithKline;MorphoSys,na,Rheumatoid arthritis,Inflammation;Multiple sclerosis;Osteoarthritis,MorphoSys HuCAL Phage Display,
Otlertuzumab,di-scFv+Fc,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD37,Trubion Pharmaceuticals;Aptevo Therapeutics,na,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma,ADAPTIR Monospecific Platform,
Oxelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2010,2011,TNFSF4,Genentech;Genmab;Roche,na,na,Allergic asthma;Allergic rhinitis,na,
Ozanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,na,na,None,None,None,2012,2013,RTN4,GlaxoSmithKline,na,na,Amyotrophic lateral sclerosis;Multiple sclerosis,na,
Ozoralizumab,Bispecific Single Domains (VH-VH'-VH),na,na,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,5m2j:D;None,2011,2012,TNFA;ALB,Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical,na,Rheumatoid arthritis,Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis,Nanobody Technology,
Pabinafusp,Whole mAb Fusion,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,TFRC,JCR Pharmaceuticals,na,Mucopolysaccharidosis II,na,na,
Pacanalotamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,TNFRSF17;CD3E,TBC,TBC,TBC,TBC,na,
Pacmilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDL1,CytomX Therapeutics,na,Solid tumours;Lymphoma,na,na,
Palivizumab,Whole mAb,G1,Kappa,Approved,NFD,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,na,na,None,2hwz:HL,None,1998,1999,RSV gpF,MedImmune,Respiratory syncytial virus infections,na,na,GS Gene Expression System,
Pamrevlumab,Whole mAb,G1,Kappa,Phase-III,Active,EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK,na,na,None,None,None,2015,2016,CTGF,FibroGen,na,Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer,Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis,na,
Panitumumab,Whole mAb,G2,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,5sx5:HL:JK/5sx4:HL:JI,None,None,2004,2005,EGFR,Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma,Colorectal cancer,Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer,Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours,Abgenix XenoMouse,
PankoMab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS,DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK,na,na,None,None,None,2016,2017,MUC1,NEMOD Biotherapeutics;Glycotope,na,Ovarian cancer;Solid tumours,na,GlycoExpress Technology,
Panobacumab,Whole mAb,M,Kappa,Phase-II,Active,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,Serotype IATS O11,Berna Biotech;Aridis Pharmaceuticals,na,Nosocomial pneumonia,na,na,
Parsatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,EGFL7,Chugai Pharmaceutical;Genentech,na,na,Colorectal cancer;Non-small cell lung cancer;Solid tumours,na,
Pasotuxizumab,Bispecific scFv,na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2014,2015,FOLH1;CD3E,Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc,na,na,Prostate cancer,na,
Pateclizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK,na,na,4mxv:HL:YX:FE/4mxw:HL:WV,None,None,2011,2012,LTA,Genentech,na,na,Rheumatoid arthritis,na,
Patritumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,ERBB3,Amgen;U3 Pharma;Daiichi Sankyo Company,na,Non-small cell lung cancer;Head and neck cancer;Breast cancer,Solid tumours,na,
Pavunalimab,Bispecific Mixed mAb and scFv,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCASSGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS,DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2020,na,LAG3;CTLA4,TBC,TBC,TBC,TBC,na,
Pavurutamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,TNFRSF17;CD3E,TBC,TBC,TBC,TBC,na,
Pembrolizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,na,na,5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC,None,None,2013,2014,PDCD1,Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society,Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma,Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections,na,na,Pembrolizumab and Lambrolizumab are the same mAb
Penpulimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,na,na,None,None,None,2020,na,PDCD1,Akeso Biopharma;Chia Tai Tianqing Pharmaceutical,na,Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Hodgkin's disease;Solid tumours,,na,
Pepinemab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK,na,na,None,None,None,2018,2019,SEMA4D,Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex,na,Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer,Multiple sclerosis,na,
Perakizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,IL17A,Roche,na,na,Psoriatic arthritis,na,
Pertuzumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,na,na,1l7i:HL/4llu:AB:CD/1s78:FE:DC,None,4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL,2003,2004,ERBB2,Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group,Breast cancer,Ovarian cancer;Brain metastases;Colorectal cancer,Gastric cancer;Non-small cell lung cancer;Prostate cancer,na,
Petosemtamab,Bispecific mAb,G1,Kappa;Kappa,Phase-I,Active,QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,EGFR;LGR5,Merus,na,Colorectal cancer;Solid tumours,na,na,
Pidilizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK,na,na,None,None,None,2012,2013,PDCD1,American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center,na,Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer,na,na,
Pimivalimab,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK,na,na,None,None,None,2020,na,PDCD1,TBC,TBC,TBC,TBC,na,
Pimurutamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLESWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK,na,na,None,None,None,2019,na,EGFR,Shanghai Henlius Biotech,na,Oncology,na,na,
Pinatuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,na,na,None,6and:HL,None,2012,2013,CD22,Genentech,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,na,
Placulumab,Single Domain Variable Fragment + Fc,G1,Kappa,Phase-II,Discontinued,na,DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNFA,Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries,na,na,Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica,na,
Plamotamab,Bispecific Mixed mAb and scFv,G1,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS,QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,MS4A1;CD3E,Xencor,na,B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma,na,na,
Plozalizumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK,na,na,None,None,None,2015,2016,CCR2,Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology,na,Atherosclerosis;Diabetic nephropathies;Malignant melanoma,Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours,Humanization by CDR Grafting,
Pogalizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,na,na,6okn:AB:CB/6ogx:CD,None,None,2015,2017,TNFRSF4,Genentech,na,na,Solid tumours;Urogenital cancer,na,Vonlerolizumab and Pogalizumab are the same mAb
Polatuzumab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,CD79B,Chugai Pharmaceutical;Genentech;Roche,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma;Follicular lymphoma,Chronic lymphocytic leukaemia,na,
Ponezumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,na,na,3u0t:BA:DC,None,None,2010,2011,APP,Rinat Neuroscience;Pfizer,na,na,Alzheimer's disease;Cerebral amyloid angiopathy,na,
Porgaviximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS,DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK,na,na,None,None,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,
Praluzatamab,Whole mAb,G1,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,CD166,CytomX Therapeutics;Immunogen,na,Solid tumours,na,na,
Prasinezumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK,na,na,None,None,None,2017,2018,SNCA,Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche,na,Parkinson's disease,na,na,
Prezalumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,None,None,None,2015,2016,ICOSLG,Amgen;MedImmune,na,na,Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus,na,May have had a former name of Prezalizumab
Pritoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS,DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 1,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,na,
Prolgolimab,Whole mAb,G1,Lambda,Phase-II/III,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS,QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL,na,na,None,None,None,2018,2019,PDCD1,Biocad,na,Malignant melanoma;Cervical cancer;Solid tumours,na,na,
Quavonlimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK,na,na,None,None,None,2019,na,CTLA4,Merck,na,Solid tumours,na,na,
Quetmolimab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK,na,na,None,None,None,2018,2019,CX3CL1,KAN Research Institute;EA Pharma;Eisai Co Ltd,na,Crohn's disease;Rheumatoid arthritis,Primary biliary cirrhosis,na,
Quilizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK,na,na,3hr5:HL:JQ:BA:IP,None,None,2011,2012,IGHE,Genentech,na,na,Allergic asthma;Allergic rhinitis;Urticaria,na,
Racotumomab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2008,2009,Idiotope of anti-NeuGc-ganliosides,Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio,Non-small cell lung cancer,Neuroblastoma,Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours,na,
Radretumab,di-scFv + CH4,E,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,na,Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Rafivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,None,None,2008,2009,RV Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,
Ragifilimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK,na,na,None,None,None,2019,na,TNFRSF18,Incyte,na,Solid tumours,na,na,
Ralpancizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,None,None,3sqo:HL,2013,2014,PCSK9,Pfizer,na,na,Hypercholesterolaemia,na,
Ramucirumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,3s34:HL/3s37:HL/3s36:HL,None,None,2008,2009,KDR,Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine,Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer,Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer,Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma,Dyax Human Phage Display,
Ranevetmab,Canine Whole mAb,G1,Kappa,Unknown,Active,EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS,DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Osterarthritis,na,PETization Technology,
Ranibizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB,2004,2004,VEGFA,Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn,Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy,Retinopathy of prematurity;Polypoidal choroidal vasculopathy,Retinal telangiectasis,na,
Ravagalimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,na,na,6pe7:HL/6pe8:HL:AB,None,None,2017,2018,CD40,AbbVie,na,Ulcerative colitis,Crohn's disease,na,
Ravulizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2017,2018,C5,Alexion Pharmaceuticals,Paroxysmal nocturnal haemoglobinuria,Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy,na,na,
Recaticimab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS,DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK,na,na,None,None,None,2020,na,PCSK9,TBC,TBC,TBC,TBC,na,
Refanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK,na,na,None,None,None,2015,2016,MAG,GlaxoSmithKline,na,na,CNS trauma;Stroke,na,
Relatlimab,Whole mAb,G4,Kappa,Phase-II/III,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK,na,na,None,None,None,2018,2019,LAG3,Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,na,
Relfovetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS,EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,NGFB,na,na,na,na,na,
Remtolumab,Bispecific Dual Variable Domain IG,G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK,4nyl:EF:AB:HL:CD/6cr1:HL;None ,3wd5:HL;None,None;None,2016,2017,IL17A;TNFA,Abbott Laboratories;Abbvie,na,na,Psoriatic arthritis;Rheumatoid arthritis,Dual Variable Domain Immunoglobulin Technology,
Reslizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,na,na,None,None,None,2001,2002,IL5,Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries,Asthma,Sinusitis;Churg-Strauss syndrome,Oesophagitis,na,
Retifanlimab,Whole mAb,G4,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDCD1,MacroGenics;Incyte Corporation;ZAI Lab,na,Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia,Haematological malignancies,na,
Revdofilimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK,na,na,None,None,None,2019,na,TNFRSF4,AbbVie,na,Solid tumours,na,na,
Rilotumumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,na,na,None,None,None,2009,2010,HGF,Amgen;Astellas Pharma,na,na,Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours,Abgenix XenoMouse,
Rinucumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS,EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR,na,na,None,None,None,2015,2016,PDGFRB,Regeneron Pharmaceuticals,na,na,Wet age-related macular degeneration,na,
Ripertamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB,4kaq:HL,None,2019,na,MS4A1,Sinocelltech,na,B-cell Lymphoma,na,na,"Chimeric, Likely to be a Rituximab biosimilar"
Risankizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK,na,na,None,None,None,2015,2016,IL23A,AbbVie;Boehringer Ingelheim,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Crohn's disease;Ulcerative colitis;Atopic dermatitis,Psoriasis;Ankylosing spondylitis;Asthma,na,
Rituximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB,4kaq:HL,None,1997,1998,MS4A1,Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis,Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection,Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus,na,
Rivabazumab,Fab,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS,DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,PcrV type III secretion system,KaloBios Pharmaceuticals Inc,na,na,Infectiology;Inflammation;Inherited diseases,Humaneering Technology,
Robatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,na,na,None,None,None,2008,2009,IGF1R,Merck & Co;Schering-Plough,na,na,Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours,na,
Roledumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS,AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT,na,na,None,None,None,2010,2011,RHD,LFB Biotechnologies,na,Haemolytic disease of newborn,na,EMABling Platform,
Rolinsatamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,PRLR,AbbVie,na,Solid tumours,na,na,
Romilkimab,Bispecific Dual Variable Domain IG,G1,Kappa;Kappa,Phase-II,Active,EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK,QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS,DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK,None;None,None;None,None;None,2017,2018,IL13;IL4,Sanofi,na,Systemic scleroderma,Idiopathic pulmonary fibrosis,na,
Romosozumab,Whole mAb,G2,Kappa,Approved,NFD,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,ChiroscienceGroup plc;Amgen;UCB,Male osteoporosis;Postmenopausal osteoporosis,na,Fracture,na,
Rontalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK,na,na,4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY,None,None,2009,2010,IFNA1,Chugai Pharmaceutical;Genentech,na,na,Systemic lupus erythematosus,na,
Rosmantuzumab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK,na,na,None,None,None,2016,2017,RSPO3,OncoMed Pharmaceuticals,na,Colorectal cancer;Solid tumours,na,na,
Rosopatamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS,DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK,na,na,None,None,None,2019,na,FOLH1,Weill Cornell Medical,na,Prostate cancer;Cancers,na,na,
Rovalpituzumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK,na,na,None,None,None,2015,2016,DLL3,Bristol-Myers Squibb;Stemcentrx,na,na,Small cell lung cancer;Solid tumours,na,
Rozanolixizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK,na,na,6fgb:HL,None,None,2016,2017,FCGRT,UCB,na,Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis,Immunological disorders,na,
Rozipafusp,Whole mAb Fusion,G2,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,None,None,None,2018,na,ICOS,Amgen,na,Rheumatoid arthritis,Systemic lupus erythematosus,na,
Ruplizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY,None,None,2000,2001,CD40LG,Biogen,na,na,Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus,na,
Sabatolimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK,na,na,None,None,None,2019,na,HAVCR2,Novartis,na,Solid tumours,na,na,
Sacituzumab,Whole mAb ADC,G1,Kappa,Preregistration,Active,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK,na,na,None,None,None,2016,2017,TACSTD2,IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University,na,Breast cancer;Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer,Pancreatic cancer;Small cell lung cancer,na,
Samalizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK,na,na,None,None,None,2010,2011,CD200,Alexion Pharmaceuticals;The Leukemia & Lymphoma Society,na,na,Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours,na,
Samrotamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK,na,na,None,None,None,2017,2018,LRRC15,AbbVie,na,na,Solid tumours,na,
Sapelizumab,Whole mAb,G2,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS,DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE,na,na,None,None,None,2015,2017,IL6R,Chugai Pharmaceutical;Roche,na,Neuromyelitis optica,Rheumatoid arthritis,na,Satralizumab and Sapelizumab are the same mAb
Sarilumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,IL6R,Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi,Rheumatoid arthritis,Giant cell arteritis;Polymyalgia rheumatica;Juvenile rheumatoid arthritis;Uveitis,Ankylosing spondylitis,VelocImmune Mouse,
Sasanlimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDCD1,Pfizer,na,Solid tumours,na,na,
Satralizumab,Whole mAb,G2,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS,DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE,na,na,None,None,None,2015,2017,IL6R,Chugai Pharmaceutical;Roche,na,Neuromyelitis optica,Rheumatoid arthritis,na,Satralizumab and Sapelizumab are the same mAb
Secukinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,na,na,None,None,None,2009,2010,IL17A,Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon,Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries,Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis,Abgenix XenoMouse,
Selicrelumab,Whole mAb,G2,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,CD40,Abramson Cancer Center of the University of Pennsylvania;Roche,na,Pancreatic cancer;Solid tumours,na,na,
Semorinemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS,DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK,na,na,None,None,None,2018,na,MAPT,AC Immune;Genentech,na,Alzheimer's disease,na,na,
Serclutamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,AbbVie,na,Solid tumours,na,na,Losatuxizumab and Serclutamab have identical variable domains
Seribantumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,na,na,None,None,None,2012,2013,ERBB3,Merrimack Pharmaceuticals;Sanofi,na,na,Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,Dyax Human Phage Display,
Serplulimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK,na,na,None,None,None,2019,2020,PDCD1,Henlix Biotech;Shanghai Henlius Biotech,na,Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B,na,na,
Setoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA,DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 2,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,na,
Setrusumab,Whole mAb,G2,Lambda,Phase-II,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL,na,na,None,None,None,2017,2018,SOST,MorphoSys;Novartis;Mereo BioPharma,na,Osteogenesis imperfecta,Hypophosphatasia;Postmenopausal osteoporosis,MorphoSys HuCAL Phage Display,
Sifalimumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,na,na,4ypg:HL:BA,None,None,2009,2010,IFNA1,Medarex;MedImmune,na,na,Myositis;Psoriasis;Systemic lupus erythematosus,na,
Siltuximab,Whole mAb,G1,Kappa,Approved,Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,na,na,None,None,None,2008,2009,IL6,Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center,Giant lymph node hyperplasia,Multiple myeloma,Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma,na,
Simlukafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK,na,na,None,None,None,2019,na,FAP,Roche,na,Solid tumours;Malignant melanoma;Renal cell carcinoma,na,na,
Simtuzumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,na,na,None,None,None,2012,2013,LOXL2,Arresto Biosciences;Gilead Sciences,na,na,Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis,na,
Sintilimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,PDCD1,Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University,Hodgkin's disease,Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours,na,na,
Sirtratumab,Whole mAb ADC,G2,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK,na,na,None,None,None,2017,na,SLITRK6,Astellas/Agensys;Seattle Genetics,na,Bladder Cancer,na,na,
Sirukumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL6,Centocor Inc;GlaxoSmithKline;Janssen Biotech,na,Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder,Rheumatoid arthritis;Atherosclerosis,na,
Sofituzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,MUC16,Genentech,na,na,Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer,na,
Solanezumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,4xxd:ED:BA,None,2008,2009,APP,Eli Lilly,na,Alzheimer's disease,na,na,
Solitomab,Bispecific scFv,na,Kappa;Kappa,Phase-I,Discontinued,EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS,ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK,DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK,None;None,None;None,None;None,2011,2012,EPCAM;CD3E,Micromet Inc;Amgen,na,na,Solid tumours,na,
Sotigalimab,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK,na,na,None,None,None,2020,na,CD40,TBC,TBC,TBC,TBC,na,
Spartalizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1,Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital,na,Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer,Neuroendocrine tumours,na,
Spesolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS,QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK,na,na,6u6u:HL,None,None,2018,2019,IL36RN,na,na,Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis,na,na,
Sugemalimab,Whole mAb,G4,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,na,PDL1,Cstone Pharmaceuticals,na,Cancers;Non-small Cell Lung Cancer;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma,na,na,
Suptavumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,RSV gpF,Regeneron Pharmaceuticals,na,na,Respiratory syncytial virus infections,VelocImmune Mouse;VelociGene,
Sutimlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS,QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK,na,na,None,None,None,2017,2018,C1S,Bioverativ;True North Therapeutics,na,Autoimmune haemolytic anaemia;Idiopathic thrombocytopenic purpura,Bullous pemphigoid;Renal transplant rejection,na,
Suvizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS,DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK,na,na,3ntc:HL,None,None,2009,2010,HIV-1 gp120,Kaketsuken;Kumamoto University;University of Missouri-Columbia,na,na,HIV-1 infections,na,
Suvratoxumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK,na,na,4u6v:HL:KM,None,None,2016,2017,Toxin A,Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune,na,Nosocomial pneumonia,na,na,
Tabalumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,TNFSF13B,Eli Lilly,na,na,Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus,na,
Tabituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK,na,na,None,None,None,2018,2019,FZD10,OncoTherapy Science;Centre Leon Berard,na,na,Synovial sarcoma,na,
Tadocizumab,Fab,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS,DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK,na,na,None,None,None,2005,2006,ITGA2B_ITGB3,PDL BioPharma;Yamanouchi,na,na,Coronary artery restenosis;Stroke;Thrombosis,na,
Tafasitamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor,na,Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,
Tafolecimab,Whole mAb,G2,Kappa,Phase-III,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Innovent Biologics,na,Hypercholesterolaemia,na,na,
Talacotuzumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,na,na,4jzj:HL:AB,None,None,2017,2018,IL3RA,CSL;Janssen Biotech,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Systemic lupus erythematosus,na,na,
Talquetamab,Bispecific mAb,G4,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2019,2020,GPRC5D;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,na,
Tamrintamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK,na,na,6vgr:HL:CD,None,None,2018,na,DPEP3,Stemcentrx,na,Ovarian cancer;Solid tumours,na,na,
Tamtuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS,DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL,na,na,None,None,1bfo:HG:FE:BA:DC,2015,2016,CD52,Aratana Pharmaceuticals,na,Canine T-cell lymphoma,na,na,
Tanezumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,na,na,4edw:HL,None,None,2008,2009,NGFB,Rinat Neuroscience;Pfizer,na,Back pain;Cancer pain;Musculoskeletal pain;Pain,Diabetic neuropathies;Postherpetic neuralgia,na,
Tanibirumab,Whole mAb,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS,NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL,na,na,None,None,None,2018,2019,KDR,PharmAbcine;3SBio,na,Glioblastoma;Breast cancer,Cancer;Choroidal neovascularisation;Solid tumours,na,Olinvacimab and Tanibirumab are the same mAb
Tarextumab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK,na,na,None,None,None,2013,2014,NOTCH2&3,OncoMed Pharmaceuticals,na,Pancreatic cancer;Small cell lung cancer,Solid tumours,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,
Tarlatamab,Bispecific scFv,na;na,Kappa;Lambda,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,na,DLL3;CD3E,TBC,TBC,TBC,TBC,na,
Tavolimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK,na,na,None,None,None,2016,2018,TNFSF4,European Network of Gynaecological Oncological Trial Groups;MedImmune,na,na,Ovarian cancer;Solid tumours,na,Tavolimab and Tavolixizumab are the same mAb
Tavolixizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK,na,na,None,None,None,2016,2018,TNFSF4,European Network of Gynaecological Oncological Trial Groups;MedImmune,na,na,Ovarian cancer;Solid tumours,na,Tavolimab and Tavolixizumab are the same mAb
Tebentafusp,scFv Fusion,na,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,CD3E,Immunocore;MedImmune,na,Malignant melanoma;Uveal melanoma,na,na,T-Beta section specific for PMEL peptide 280-288 presented by MH1
Tebotelimab,Bispecific scFv with Crossover,G4,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK,None;None,None;None,None;None,2019,na,PDCD1;LAG3,MacroGenics,na,Solid tumours;Hematologic-blood cancer,na,na,
Teclistamab,Bispecific mAb,G4,Lambda;Lambda,Phase-I,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2018,na,TNFRSF17;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,na,
Telazorlimab,Whole mAb,G1,Kappa,Phase-II,Active,QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK,na,na,None,None,None,2019,na,TNFRSF4,Glenmark Pharmaceuticals,na,Atopic dermatitis,na,na,
Telisotuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,MET,Pierre Fabre;AbbVie,na,na,Solid tumours,na,
Temelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS,QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,MRSV envelope protein,GeNeuro,na,Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy,na,na,
Tenatumomab,Whole mAb Radiolabelled,G2b,Kappa,Phase-I,Discontinued,EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK,na,na,None,None,None,2007,2008,TNC,sigma-tau SpA,na,na,Cancer,na,
Teplizumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,na,na,None,None,None,2007,2008,CD3E,Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics,na,Type 1 diabetes mellitus,Multiple sclerosis;Psoriasis;Psoriatic arthritis,na,
Tepoditamab,Bispecific mAb,G1,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2017,2018,CLEC12A;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,na,
Teprotumumab,Whole mAb,G1,Kappa,Preregistration,Active,QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK,na,na,None,None,None,2009,2010,IGF1R,Genmab;Roche;Horizon Therapeutics plc,na,Graves ophthalmopathy,Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours,Medarex UltiMAb Mouse,
Tesidolumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL,na,na,None,None,None,2014,2015,C5,MorphoSys;Novartis,na,Paroxysmal nocturnal haemoglobinuria,Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,
Tesnatilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2019,na,KLRK1,Janssen Research & Development,na,Crohn's disease,na,na,
Tezepelumab,Whole mAb,G2,Lambda,Phase-III,Active,QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,5j13:CB,None,None,2015,2016,TSLP,Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia,na,Asthma;Atopic dermatitis,na,na,
Tibulizumab,Bispecific Mixed mAb and scFv,G4,Kappa;Kappa,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK,None;None,None;None,None;6nou:AA/6nov:AB,2017,2018,TNFSF13B;IL17A,Eli Lilly,na,na,Rheumatoid arthritis;Sjogren's syndrome,na,
Ticilimumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,na,na,5ggu:HL:AB/5ggv:HL,None,None,2005,2008,CTLA4,AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine,na,Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer;Diffuse large B cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes;Vulvovaginal cancer,na,Abgenix XenoMouse,Tremelimumab and Ticilimumab are the same mAb
Tidutamab,Bispecific Mixed mAb and scFv,G1,Kappa;Lambda,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2018,na,SSTR2;CD3E,ICON;Xencor,na,Gastrointestinal stromal tumours;Neuroendocrine tumours,na,na,
Tigatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,na,na,None,None,None,2007,2008,TNFRSF10B,Daiichi Sankyo Company;University of Alabama at Birmingham,na,na,Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer,na,
Tilavonemab,Whole mAb,G4,Kappa,Phase-II,Active,EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK,na,na,None,None,None,2018,na,MAPT,AbbVie;C2N Diagnostics,na,Alzheimer's disease;Progressive supranuclear palsy,na,na,
Tildrakizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,IL23A,Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries,Plaque psoriasis,Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis,Autoimmune disorders,na,
Tilogotamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTVEIK,na,na,None,None,None,2019,na,TNFRSF10B,Genmab,na,Solid tumours,na,na,
Tilvestamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,AXL,BerGenBio,na,Cancer,na,na,
Timigutuzumab,Whole mAb,G1,Kappa,Phase-I,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD,1fve:BA:DC/4x4x:AB:CD/6bgt:BA,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2,Roche,Breast cancer,na,na,na,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp have identical V domain.
Timolumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS,VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,AOC3,Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation,na,Primary sclerosing cholangitis,Inflammation;Plaque psoriasis;Rheumatoid arthritis,na,
Tinurilimab,Whole mAb,G2,Kappa,Phase-I,Active,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,CEACAM6,Bayer;German Cancer Research Center,na,Solid tumours,na,na,
Tiragolumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK,na,na,None,None,None,2017,2018,TIGIT,Genentech,na,Non-small cell lung cancer;Solid tumours,na,na,
Tislelizumab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,PDCD1,BeiGene;Celgene Corporation,na,Hodgkin's disease;Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Urogenital cancer;Solid tumours;Ovarian cancer;Renal cancer,na,na,
Tisotumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS,DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,F3,Genmab;Seattle Genetics,na,Bladder cancer;Cervical cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours,na,na,
Tocilizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,na,na,None,None,None,2004,2004,IL6R,Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh,Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis,Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer,Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus,na,
Tomaralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK,na,na,None,None,None,2018,na,TLR2,Opsona Therapeutics,na,Delayed graft function;Myelodysplastic syndromes;Cancer,Autoimmune disorders;Inflammation,na,
Tomuzotuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,None,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,2016,2017,EGFR,Glycotope,na,Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours,na,GlycoExpress Technology,
Toripalimab,Whole mAb,G4,Kappa,Approved,Active,QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK,na,na,6jbt:HL,None,None,2018,2019,PDCD1,Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University,Malignant melanoma,Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer,na,na,
Tosatoxumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS,QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL,na,na,None,None,None,2013,2014,Toxin A,Aridis Pharmaceuticals;Kenta Biotech,na,Nosocomial pneumonia,Sepsis,na,
Tovetumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,na,na,None,None,None,2013,2014,PDGFRA,Cambridge Antibody Technology;MedImmune,na,na,Glioblastoma;Non-small cell lung cancer;Solid tumours,na,
Tralokinumab,Whole mAb,G4,Lambda,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,na,na,5l6y:HL,None,None,2009,2010,IL13,Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune,na,Atopic dermatitis;Alopecia areata,Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis,na,
Trastuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED,1fve:BA:DC/4x4x:AB:CD/6bgt:BA,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2,Roche,Breast cancer,na,na,na,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp have identical V domain.
Tregalizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CD4,Biotest AG,na,na,Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis,na,
Tremelimumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,na,na,5ggu:HL:AB/5ggv:HL,None,None,2005,2008,CTLA4,AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine,na,Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer;Diffuse large B cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes;Vulvovaginal cancer,na,Abgenix XenoMouse,Tremelimumab and Ticilimumab are the same mAb
Trevogrumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS,DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Regeneron Pharmaceuticals;Sanofi,na,Muscular atrophy;Musculoskeletal disorders,na,VelocImmune Mouse,
Tusamitamab,Whole mAb,G1,Kappa,TBC,Active,EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS,DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK,na,na,None,None,None,2020,na,CEACAM5,TBC,TBC,TBC,TBC,na,
Ublituximab,Whole mAb,G1,Kappa,Phase-III,Active,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK,na,na,None,None,None,2010,2011,MS4A1,LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc,na,Chronic lymphocytic leukaemia;Multiple sclerosis;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma;Neuromyelitis optica,na,EMABling Platform,
Ulocuplumab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK,na,na,None,None,None,2013,2014,CXCR4,Bristol-Myers Squibb;Medarex;University of Bari,na,Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Multiple myeloma;Neuroectodermal tumours,B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma ,na,
Upifitamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK,na,na,None,None,None,2019,na,SLC34A2,Mersana Therapeutics,na,Solid tumours,na,na,
Urabrelimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK,na,na,None,None,None,2019,na,CD47,Surface Oncology,na,Cancers;Multiple myeloma,na,na,
Urelumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,na,na,6mhr:AB:DE,None,None,2010,2011,TNFRSF9,Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex,na,Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma,Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer,Medarex UltiMAb Mouse,"Jain paper: ""VL sequence modified at one position to match patent document (US7659384) and JK germline"""
Ustekinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,na,na,3hmw:HL/3hmx:HL,None,None,2008,2009,IL12B,Centocor Inc;Janssen Biotech;Medarex,Crohn's disease;Plaque psoriasis;Psoriatic arthritis,Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis,Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis,Medarex UltiMAb Mouse,
Utomilumab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL,na,na,6a3w:GH:DE:AB:JK/6mi2:DE:AB,None,None,2016,2017,TNFRSF9,Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer,na,Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Colorectal cancer;Follicular lymphoma;Ovarian cancer,Non-Hodgkin's lymphoma,MorphoSys HuCAL Phage Display,
Vadastuximab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD33,Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,
Valanafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK,na,na,None,5kqv:PQ:CD/4zxb:CD,3loh:CD/2dtg:CD/3w14:CD:PQ,2017,2018,INSR,ArmaGen Technologies,na,Mucopolysaccharidosis I,na,na,
Vanalimab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL,na,na,None,None,None,2017,2019,CD40,Alligator Bioscience;Janssen Biotech,na,Solid tumours,na,na,Mitazalimab and Vanalimab are the same mAb
Vandortuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,STEAP1,Roche;Genentech,na,na,Cancers;Prostate Cancer,na,
Vantictumab,Whole mAb,G2,Lambda,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL,na,na,None,None,None,2013,2014,FZD Family,Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals,na,Breast cancer;Non-small cell lung cancer;Pancreatic cancer,na,MorphoSys HuCAL Phage Display,
Vanucizumab,Bispecific mAb,G1,Lambda;Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ,None;None,None;6bft:AB:HL/1cz8:HL:YX,2014,2015,ANGPT2;VEGFA,Roche,na,na,Solid tumours;Colorectal cancer,na,
Varisacumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS,DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,VEGFA,Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS,na,Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer,na,na,
Varlilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,CD27,Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia,na,Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioma,Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer,na,
Vatelizumab,Whole mAb,G4,Kappa,Phase-II/III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS,DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK,na,na,None,None,None,2011,2012,ITGA2,Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi,na,na,Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis,na,
Vedolizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,ITGA4_ITGB7,Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology,Crohn's disease;Ulcerative colitis,Graft-versus-host disease;Coeliac disease;Malignant melanoma,na,na,
Veltuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,na,na,None,None,None,2007,2008,MS4A1,Immunomedics;Weill Cornell Medical College,na,Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma,Chronic lymphocytic leukaemia;Rheumatoid arthritis,na,
Vesencumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK,na,na,2qqn:HL,None,None,2010,2011,NRP1,Genentech;Roche,na,na,Solid tumours,na,
Vibecotamab,Bispecific Mixed mAb and scFv,G1,Kappa;Kappa,Phase-I,Active,QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,na,IL3RA;CD3E,Xencor,na,Haematological malignancies,na,na,
Vibostolimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK,na,na,None,None,None,2019,2020,TIGIT,Merck,na,Solid tumours,na,na,
Vilobelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2019,na,C5,InflaRX,na,Hidradenitis suppurativa;Inflammation,na,na,Chimeric
Visilizumab,Whole mAb,G2,nd,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2000,2001,CD3E,PDL BioPharma,na,na,Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis,na,
Vixarelimab,Whole mAb,G4-G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL,na,na,None,None,None,2020,na,OSMR,Kiniksa Pharmaceuticals,na,Prurigo nodularis;Pruritus;Atopic dermatitis,na,na,
Vobarilizumab,Bispecific Single Domains (VH-VH'),na,na,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2015,2016,IL6R;ALB,Ablynx,na,Rheumatoid arthritis;Systemic lupus erythematosus,na,Nanobody Technology,
Vofatamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK,na,na,None,None,4wv1:BA:ED/3grw:HL,2018,na,FGFR3,BioClin Therapeutics;Rainier Therapeutics,na,Bladder cancer;Urogenital cancer;Achondroplasia,Multiple myeloma;Solid tumours,na,
Volagidemab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,na,na,None,4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL,None,2018,na,GCCR,Amgen;REMD Biotherapeutics,na,Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders,na,na,
Vonlerolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,na,na,6okn:AB:CB/6ogx:CD,None,None,2015,2017,TNFRSF4,Genentech,na,na,Solid tumours;Urogenital cancer,na,Vonlerolizumab and Pogalizumab are the same mAb
Vopratelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK,na,na,None,None,None,2017,2018,ICOS,Jounce Therapeutics,na,Solid tumours,na,na,
Vorsetuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,CD70,Seattle Genetics,na,na,Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis,na,
Vudalimab,Bispecific Mixed mAb and scFv,G1,Kappa;Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None,2020,na,CTLA4;PDCD1,TBC,TBC,TBC,TBC,na,
Vulinacimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2019,na,VEGFR2,Henlix,na,Solid tumours,na,na,
Vunakizumab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK,na,na,None,None,None,2016,2017,IL17A,Atridia;Jiangsu Hengrui Medicine Co.,na,Plaque psoriasis;Psoriasis;Spondylarthritis,Autoimmune disorders,na,
Xentuzumab,Whole mAb,G1,Lambda,Phase-II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS,DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL,na,na,None,None,None,2015,2016,IGF1&IGF2,Boehringer Ingelheim;Eli Lilly,na,Breast cancer;Prostate cancer,Non-small cell lung cancer;Solid tumours,MorphoSys HuCAL Phage Display,
Zagotenemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,MAPT,Eli Lilly,na,Alzheimer's disease,na,na,
Zalifrelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,na,CTLA4,4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma,na,Non-small cell lung cancer;Cervical cancer;Cancer,na,na,
Zalutumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2005,2006,EGFR,Danish Head and Neck Cancer Group;Genmab,na,na,Head and neck cancer;Colorectal cancer;Non-small cell lung cancer,na,
Zampilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS,DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK,na,na,None,None,None,2018,2019,TGM2,UCB,na,Autoimmune disorders,na,na,
Zanidatamab,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED,None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA,1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2;ERBB2,Zymeworks,na,Gastric cancer;Oesophageal cancer;Breast cancer;Solid tumours,Ovarian cancer,na,Biparatopic Bispecific
Zanolimumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,CD4,Emergent BioSolutions;Genmab,na,na,Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis,Medarex HuMAb Mouse,
Zatuximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK,na,na,None,None,None,2012,2013,EGFR,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,na,Futuximab and Zatuximab are the same mAb
Zelminemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK,na,na,None,None,None,2019,na,ADCYAP1R1,Amgen,na,Migraine,na,na,
Zenocutuzumab,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,5o4o:BA/5o7p:BA;5o4g:BA,None;None,None;None,2017,2018,ERBB3;ERBB2,Merus,na,Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer,Endometrial cancer;Ovarian cancer,GlymaxX Technology,
Ziltivekimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK,na,na,None,None,None,2019,2020,IL6,AstraZeneca;Corvidia,na,Cardiovascular disorders,na,na,
Zimberelimab,Whole mAb,G4,Lambda,Phase-II,Active,QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL,na,na,None,None,None,2020,na,PDCD1,Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology,na,Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours;Hodgkin's disease,na,na,
Zolbetuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,na,na,None,None,None,2017,2018,CLDN18,Ganymed Pharmaceuticals,na,Gastric cancer;Oesophageal cancer;Pancreatic cancer;Solid tumours,na,na,Zolbetuximab and Claudiximab are the same mAb
Zolimomab,Whole mAb,G2a,Kappa,Approved,Discontinued,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,na,na,1sy6:HL,None,None,1988,1989,CD3E,Cancer Research UK;Ortho-McNeil;XOMA,na,na,Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis,na,Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.
Zuberitamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDYSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS,DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK,na,na,None,None,3bky:HL,2019,na,MS4A1,Zhejiang Hisun Pharmaceutical,na,Diffuse large B-cell lymphoma,na,na,Chimeric
